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Summary 
Significance of colonoscopy in screening for colorectal cancer 
Colonoscopy is – irrespective of first line screening test – the final common 
pathway of all screening for colorectal cancer (CRC) and is used for biopsy 
and polyp removal. For a screening-test in the (healthy) general population 
colonoscopy is invasive and prone to (unlikely) serious complications. 
Screening-yield and rates of complications are strongly dependent on the 
individual operator and on quality assurance. As a result, training and con-
tinued education of endoscopists as well as monitoring of both detection and 
complication rates are key to high screening-quality. 
 
Effectiveness of screening for CRC 
No data is currently available on the impact of CRC-screening on all-cause 
mortality. Four randomized controlled trials on screening for faecal occult 
blood as a first-line test (gFOBT) showed a relative risk reduction of 15% for 
disease-specific CRC-mortality. Absolute risk reduction was between 0.12-
0.29%. Two large non-population based randomized controlled trial on 
once-only flexible sigmoidoscopy as a first-line screening-test showed a rela-
tive risk reduction of 31% and 22% (statistically not significant) for disease-
specific CRC-mortality and a reduction of CRC incidence of 23% and 18%. 
Results from a large non-population based two round flexible sigmoidoscopy 
screening study showed a relative risk reduction of 26% of disease-specific 
CRC-mortality and a reduction of CRC incidence of 21%. Absolute risk re-
duction of CRC-mortality through flexible sigmoidoscopy was between 0.11-
0.15%. Results from a population based randomized trials on flexible sig-
moidoscopy are expected in 2013. To date there is no evidence from random-
ized controlled trials on CRC-screening using colonoscopy as a first-line 
screening test. Two randomized studies on screening with either colono-
scopy or iFOBT as a first-line test will yield results starting ten years from 
now. There is only limited evidence on test characteristics (sensitivity, speci-
ficity, complication rates) in real life screening-settings. The ideal test 
strategie in CRC-screening is uncertain, the evidence base evolving. 
 
colonoscopy … 
… final common 
pathway in all CRC-
screening 
… invasive, (unlikely) 
serious complications 
… operator-dependent 
limited evidence base 
for CRC-screening … 
… RCTs from gFOBT 
and recently flexible 
sigmoidoscopy show 
reduction in CRC-
specific mortality … 
… for flexible 
sigmoidoscopy also for 
CRC-incidence 
no RCT evidence for 
colonoscopy for another 
decade 
ideal CRC-screening test 
strategy uncertain 
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Summary 1: results from CRC-screening-RCTs on effectiveness 
Study 
Country 
Duration of follow-up 
CRC-mortality 
(95% CI) 
CRC-incidence 
(95% CI) 
NNS 
(95% CI) 
gFOBT 
gFOBT Nottingham 
UK4 
Follow-up: 11 yrs. 
RR3: 0.86 (0.77-0.97) 
ARR: 0.12%1 
RR5: 1.04 (0.95-1.14) NNS (death from CRC): 
8401 
gFOBT Funen 
DK4 
Follow-up: 17 yrs. 
RR3: 0.84 (0.73-0.96) 
ARR: 0.22%1 
RR5: 1.02 (0.93-1.12) NNS (death from CRC): 
4491 
gFOBT Gotenburg 
SWE4 
Follow-up: 15.5 yrs. 
RR3: 0.84 (0.71-0.99) 
ARR: 0.14%1 
RR5: 0.96 (0.86-1.06) NNS (death from CRC): 
7111 
gFOBT Minnesota 
USA4 
Follow-up: 18 yrs. 
RR3: 0.75 (0.62-0.91) 
ARR: 0.29%1 
RR5: 0.83 (0.73-0.94) NNS (death from CRC): 
3501 
Flexible sigmoidoscopy 
FS Atkin (2010) 
UK 
Follow-up: 11.2 yrs. 
RR: 0.69 (0.59-0.82; 
p<0.0001) 
ARR: 0.15%1 
RR: 0.77 (0.70-0.84; 
p<0.0001) 
ARR: 0.37%1 
NNS (death from CRC): 
489 (343-852) 
NNS (CRC-diagnosis): 
191 (145-277) 
FS Segnan (2011) 
ITA 
Follow-up: 
11.4 yrs. mortality 
10.5 yrs. incidence 
RR: 0.78 (0.56-1.08) 
ARR: 0.105% 
RR: 0.82 (0.69-0.96) 
ARR: 0.32%1 
NNS (death from CRC): 
9521 
NNS (CRC-diagnosis): 
3121 
FS Schoen (2012) 
USA 
Follow-up: 11.9 yrs. 
RR: 0.74 (0.63-0.87; 
p<0.001) 
ARR: 0.115%1 
RR: 0,79 (0.72-0.85; 
p<0.001) 
ARR: 0.36%1 
NNS (death from CRC): 
8712 
NNS (CRC-diagnosis): 
2822 
ARR … absolute risk reduction; CI … confidence interval; CRC … colorectal cancer; FS … flexible 
sigmoidoscopy; gFOBT … guaiac fecal occult blood test; NNS … number needed to screen; RR … relative 
risk 
1 own calculation 
2 author response to letter to the editors: http://www.nejm.org/doi/full/10.1056/NEJMoa1114635#t=letters 
3 Bretthauer (2011), figure 3 
4 Cochrane Review on gFOBT RCTs: Cochrane Systematic Review, Hewitson (2007) 
5 Bretthauer (2011), table 3 
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International screening-activities 
In many countries the evaluation of evidence, the planning and at times the 
coordination of CRC-screening are done by a national institution. A few 
countries – e.g. England, Scotland, Finland, Ireland, the Netherlands and 
Australia – run or are starting to run organized population-based programs. 
However, most screening is not population-based but opportunistic with low 
participation rates. Some countries – Japan, Italy and Germany – have pro-
grams that have been under way for many years. In the European Union 
about 70% of the population has access to some mode of CRC-screening. 
The most common first-line screening-test is gFOBT, to a growing degree al-
so iFOBT. In some countries endoscopic-screening – colonoscopy, flexible 
sigmoidoscopy – is used as an alternative or in combination with FOBT. Al-
so due to insurers’ remuneration decisions in the US, colonoscopy is the 
most common first-line screening-test there. 
 
Choice of first-line test 
When considering first-line screening-tests on which to base an organized 
program, program sensitivity per invitee through the test’s impact on par-
ticipation in screening (and re-screening) is more important than single test-
sensitivity per screened participant. Complications rates are to be taken into 
account. Program-sensitivity largely depends on participation rates. Recent 
developments in first-line screening tests include quantitative iFOBTs. CT-
colonoscopy, capsule endoscopy and new molecular tests are not yet viable 
alternatives for use in population-based mass-screening. 
Summary 2: CRC-screening participation rates observed in the real world 
Screening- 
modality 
Source 
Country 
Participation- 
rate 
Comment 
Screening-programs 
gFOBT von Wagner 
(2011) 
UK 
54% Oct. 2006 – Jan. 2009, mailing of first self-test kit 
population based program 
gFOBT Poncet (2012) 
France 
37% 2007-2008, 
population based program 
gFOBT Cancer Society of 
Finland (2012) 
Finland 
66.3% 2011 
population based program in 154 of Finland‘s 444 mu-
nicipalities 
iFOBT AIHW (2012) 
Australien 
38.5% Aug. 2006 – June 2011, 
population based program 
iFOBT Zorzi (2012) 
Italy 
48% 2010, adjusted participation rate (only persons actu-
ally invited included), 
population based program 
FS Zorzi (2012) 
Italy 
24% 2010, adjusted participation rate (only persons actu-
ally invited included), 
population based program 
C ZI (2012) 
Germany 
18.3% of men 
20.1% of  
females 
cumulated attendance 2003-2010, 
program not population based 
most screening-activity 
not population-based … 
… but opportunistic 
with low participation 
rates 
… gFOBT most 
common, also iFOBT 
starting to be used … 
… US relies mostly on 
colonoscopy 
first-line screening test’s 
impact on program 
participation more 
important than 
sensitivity of single test 
complication rates 
should be considered 
Screening for Colorectal Cancer 
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Screening- 
modality 
Source 
Country 
Participation- 
rate 
Comment 
RCTs 
gFOBT Hol (2010) 
NL 
49.5% RCT in preparation of organized CRC-screening pro-
gram in the NL, population based randomization, first 
round of invitation 
iFOBT Hol (2010) 
NL 
61.5% RCT in preparation of organized CRC-screening pro-
gram in the NL, population based randomization, first 
round of invitation 
iFOBT Van Hal (2011) 
Belgium 
44.3% RCT pilot study for potential organized CRC-screening 
program in Belgium, population based randomization, 
(52.3% participation after invitation via mail, 27.7% 
after invitation via general practicioner) 
FS Hol (2010) 
NL 
32.4% RCT in preparation of organized CRC-screening pro-
gram in the NL, population based randomization, first 
round of invitation 
C Stoop (2012) 
NL 
22% RCT in preparation of organized CRC-screening pro-
gram in the NL, population based randomization, first 
round of invitation 
CT-C Stoop (2012) 
NL 
34% RCT in preparation of organized CRC-screening pro-
gram in the NL, population based randomization, first 
round of invitation 
C … colonoscopy; CT-C … virtual CT-colonoscopy; FS … flexible sigmoidoscopy , gFOBT … guaiac fecal occult 
blood test; iFOBT immunochemical fecal occult blood test 
 
Summary 3: estimates of (single-)test characteristics of different screening-modalities 
Screening-test Sensitivity (%) 
CRC 
Sensitivity (%) 
Advanced adenoma
Specificity (%) 
CRC 
Specificity (%) 
Advanced adenoma
gFOBT 11-64 11-41 91-98 n.a. 
iFOBT 56-89 27-56 91-97 n.a. 
Flexible  
Sigmoidoskopie 
60-70 50-81 60-70 50-80 
Koloskopie 95 95 95-99 90-95 
CRC … colorectal cancer; gFOBT … guaiac fecal occult blood test; iFOBT immunochemical fecal occult blood 
test; n.a. … not applicable 
Source: Bretthauer (2011), table 1 
 
Summary 4: complications in CRC-screening-RCTs on flexible sigmoidoscopy: complications FS 
Study Perforations per 100,000 Bleedings per 100,000 
Atkin (2010)1 2.48 302 
Segnan (2011) 10 n.a. 
Schoen (2012) 2.8 
2. FS round: 107.53 
n.a. 
1reported in Atkin (2002) 
2 hospital admission 
3 author response to letter to the editors: http://www.nejm.org/doi/full/10.1056/NEJMoa1114635#t=letters  
Summary 
LBI-HTA | 2012 9 
Summary 5: complications in CRC-screening-RCTs on flexible sigmoidoscopy: complications colonoscopy 
following FS 
Study Perforations per 100,000 Bleedings per 100,000 
Atkin (2010)1 168 3772 
Segnan (2011) 120 n.a. 
Schoen (2012) 108 n.a. 
1reported in Atkin (2002) 
2 hospital admission 
 
Improving screening-effectiveness 
An upper age-limit for CRC-screening is recommended. An integrated 
screening-program combines screening with screening-relevant considera-
tions in diagnosis, treatment and surveillance. Along with standardized doc-
umentation and regular evaluation an integrated program-design provides 
the quality necessary to consider screening average risk-populations. Giving 
thorough attention to the design of the surveillance regime is important, be-
cause its thresholds determine the numbers of surveillance-colonoscopies re-
sulting from CRC-screening. Incremental implementation of a national 
population-based screening-program, with targeted research studies, pilot 
testing and incremental roll-out, like in the Netherlands, should be consid-
ered. 
 
Securing comprehensive program-financing 
Population-based screening-programs require significant initial investment 
in overhead and sustainable financing of ongoing documentation, quality as-
surance and evaluation. Also, ongoing financing of both program- and pro-
vider-independent information dissemination to potential screening-
participants enabling informed consent if or if not to participate in screen-
ing, and funds for regular program evaluation through an external institu-
tion need to be secured. 
integrated screening – 
program considering 
diagnosis – treatment – 
surveillance 
incremental 
implementation of 
national program 
recommended 
CRC-screening needs 
substantial initial net-
investment, 
comprehensive and 
sustainable program 
funding needs to be 
secured 
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Zusammenfassung 
Bedeutung der Koloskopie im Dickdarmkrebs-Screening 
Koloskopie ist – unabhängig von der Wahl des first-line Tests – Bestandteil 
jedes Screenings. Koloskopie wird jedenfalls als second-line Test und gege-
benenfalls zur Biopsie bzw. Entfernung entdeckter Polypen eingesetzt. Ko-
loskopie ist für eine Screening-Maßnahme, die sich an die gesunde Normal-
bevölkerung richtet, invasiv und mit (seltenen) schweren Komplikationen 
verbunden. Die Entdeckungsraten von Polypen und die Komplikationsraten 
sind stark von der/dem individuellen UntersucherIn und von umfassender 
Qualitätssicherung abhängig. Die Aus- und Weiterbildung der Endoskopie-
renden und das Monitoring der Ergebnisraten sind zentral für die Qualität 
von Dickdarmkrebs-Screening. 
 
Effektivität von Dickdarmkrebs-Screening 
Zum Einfluss von Darmkrebs-Screening auf die Gesamtsterblichkeit liegen 
keine Daten vor. Vier randomisierte Studien belegen für Screening mit ei-
nem Test auf Blut im Stuhl (gFOBT) eine Senkung der Darmkrebs-
spezifischen Sterblichkeit um 15% (relative Risikoreduktion). Die absolute 
Risikoreduktion liegt zwischen 0,12-0,29%. Zwei große nicht-
populationsbezogene randomisierte Studien belegen für einmaliges Scree-
ning mit flexibler Sigmoidoskopie eine Senkung der CRC-spezifischen 
Sterblichkeit um 31% bzw. (statistisch nicht signifikant) 22%. Die Inzidenz 
von CRC ging um 23% bzw. 18% zurück. Eine große nicht-
populationsbezogene randomisierte Studie zu Screening mit zwei Runden 
flexibler Sigmoidoskopie belegt 26% weniger CRC-spezifische Sterblichkeit 
und 21% weniger CRC-Inzidenz. Die absoluten Risikoreduktionen der 
CRC-spezifischen Sterblickeit durch flexible Sigmoidoskopie liegen zwi-
schen 0,11-0,15%. Ergebnisse einer weiteren, diesmal populationsbezogenen, 
randomisierter Studie zu flexibler Sigmoidoskopie werden 2013 erwartet. 
Zwei randomisierte Studien über Screening mit Koloskopie oder alternativ 
iFOBT als first-line Test werden erst in zehn Jahren Ergebnisse liefern. 
Über Charakteristika wie Sensitivität, Spezifität und Komplikationsraten 
der Tests im Kontext von Screening-Bedingungen in der Praxis gibt es we-
nig Evidenz. Eine ideale Teststrategie von CRC-Screening läßt sich derzeit 
aus der vorhandenen Evidenz nicht ableiten, das Forschungsgebiet entwi-
ckelt sich dynamisch. 
Koloskopie … 
… ist Hauptbestandteil 
jedes CRC-Screening 
Pfads 
... ist invasive Screening-
Massnahme mit 
(seltenen) schweren 
Komplikationen 
wenig Evidenz zur 
Effektivita¨t von 
Dickdarmkrebs-
Screening vorhanden 
… 4 RCTs zu gFOBT und 
… 
… 3 RCTs zu flexibler 
Sigmoidskopie belegen 
Reduktion der CRC-
Mortalita¨t durch 
Screening … 
… flexible 
Sigmoidoskopie auch 
der CRC-Inzidenz 
… RCTs zu Koloskopie 
erst in 10 Jahren 
Zusammenfassung 
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Ergebnisse von CRC-Screening-RCTs zur Effektivität 
Studie 
Land 
Follow-up 
CRC-Mortalita¨t 
(95% CI) 
CRC-Inzidenz 
(95% CI) 
NNS 
(95% CI) 
gFOBT 
gFOBT Nottingham 
UK4 
Follow-up: 11 J. 
RR3: 0,86 (0,77-0,97) 
ARR: 0,12%1 
RR5: 1,04 (0,95-1,14) NNS (CRC-Todesfall): 
8401 
gFOBT Funen 
DK4 
Follow-up: 17 J. 
RR3: 0,84 (0,73-0,96) 
ARR: 0,22%1 
RR5: 1,02 (0,93-1,12) NNS (CRC-Todesfall): 
4491 
gFOBT Go¨teburg 
SWE4 
Follow-up: 15,5 J. 
RR3: 0,84 (0,71-0,99) 
ARR: 0,14%1 
RR5: 0,96 (0,86-1,06) NNS (CRC-Todesfall): 
7111 
gFOBT Minnesota 
USA4 
Follow-up: 18 J. 
RR3: 0,75 (0,62-0,91) 
ARR: 0,29%1 
RR5: 0,83 (0,73-0,94) NNS (CRC-Todesfall): 
3501 
Flexible Sigmoidoskopie 
FS Atkin (2010) 
UK 
Follow-up: 11,2 J. 
RR: 0,69 (0,59-0,82; 
p<0,0001) 
ARR: 0,15%1 
RR: 0,77 (0,70-0,84; 
p<0,0001) 
ARR: 0,37%1 
NNS (CRC-Todesfall): 
489 (343-852) 
NNS (CRC-Diagnose): 
191 (145-277) 
FS Segnan (2011) 
ITA 
Follow-up: 
11,4 J. Mortalita¨t 
10,5 J. Inzidenz 
RR: 0,78 (0,56-1,08) 
ARR: 0,105% 
RR: 0,82 (0,69-0,96) 
ARR: 0,32%1 
NNS (CRC-Todesfall): 
9521 
NNS (CRC-Diagnose): 
3121 
FS Schoen (2012) 
USA 
Follow-up: 11,9 J. 
RR: 0,74 (0,63-0,87; 
p<0,001) 
ARR: 0,115%1 
RR: 0,79 (0,72-0,85; 
p<0,001) 
ARR: 0,36%1 
NNS (CRC-Todesfall): 
8712 
NNS (CRC-Diagnose): 
2822 
ARR … absolute risk reduction; CI … Konfidenzintervall; CRC … Colorectalcarci-
nom; FS … flexible Sigmoidoskopie; gFOBT … guaiac fecal occult blood test; 
NNS … number needed to screen; RR … relative risk 
1 eigene Berechnung 
2 author response to letter to the editors: 
http://www.nejm.org/doi/full/10.1056/NEJMoa1114635#t=letters 
3 Bretthauer (2011), Abbildung 3 
4 Cochrane Review zu gFOBT RCTs: Cochrane Systematic Review, Hewitson (2007) 
5 Bretthauer (2011), Tabelle 3 
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Screening-Aktivitäten international 
In vielen Ländern erfolgt die Bewertung der Evidenz, die Planung und teil-
weise die Koordinierung von Screening durch eine nationale Institution. 
Nur wenige Länder – wie England, Schottland, Finnland, Irland, die Nie-
derlande und Australien – verfügen über nationale populationsbezogene 
Programme. Meist erfolgt Screening aber nicht populationsbezogen im 
Rahmen eines qualitätsgesicherten Programms, sondern opportunistisch 
und mit niedriger Teilnahmerate. In einigen Ländern – wie etwa in Japan, 
Italien und Deutschland – bestehen Programme bereits seit vielen Jahren. 
In der Europäischen Union haben etwa 70% der Bevölkerung Zugang zu der 
einen oder anderen Form von Dickdarmkrebs-Screening. Als first-line 
Screening-Test wird am häufigsten gFOBT, zunehmend gefolgt von iFOBT, 
eingesetzt. Bisweilen besteht eine Wahlmöglichkeit zu Koloskopie oder fle-
xibler Sigmoidoskopie. Nicht zuletzt aufgrund von Erstattungsentscheidun-
gen von Krankenversicherungen in den USA ist dort Koloskopie der häu-
figste first-line Test. 
 
Auswahl eines first-line Tests 
Für die Auswahl eines first-line Screening-Tests ist seine Auswirkung auf 
die TeilnehmerInnenrate des Screening-Programms wichtiger als die-
Sensitivität eines einzelnen Tests. Die Sensitivität des Programms hängt 
maßgeblich von der TeilnehmerInnenrate über die Screeningrunden hinweg 
ab. Die Komplikationsraten von endoskopischen Tests (flexible Sigmoi-
doskopie und Koloskopie) sind in Betracht zu ziehen. Als neue first-line 
Screening-Tests bieten sich quantitative iFOBTs an. CT-Koloskopie, Kap-
selendoskopie und in Entwicklung befindliche molekulare Test werden in 
absehbarer Zeit (noch) keine Alternativen für einen breiten Screening-
Einsatz sein. 
Screening meist nicht 
populationsbezogen im 
Rahmen 
qualita¨tsgesicherter 
Programme … 
… sondern 
opportunistisch und mit 
niedrigen 
Teilnahmeraten 
… gFOBT, iFOBT, in 
USA Kolonoskopie 
Auswahl des Screening-
Tests: 
… Auswirkung auf 
Programmsensivita¨t 
u¨ber Teilnahmerate 
wichtiger … 
… als Einzelsensitivita¨t 
des Tests 
Komplikationsraten  
Zusammenfassung 
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Real beobachtete Teilnahmeraten an CRC-Screening 
Screening- 
Modalita¨t 
Quelle 
Land 
Teilnahme- 
rate 
Bemerkung 
Screening-Programme 
gFOBT von Wagner (2011) 
UK 
54% Okt. 2006 – Jan. 2009, Zusendung des ersten 
Selbsttest-Briefchens, 
populationsbezogenes Programm 
gFOBT Poncet (2012) 
Frankreich 
37% 2007-2008, 
populationsbezogenes Programm 
gFOBT Cancer Society of 
Finland (2012) 
Finnland 
66,3% 2011 
populationsbezogenes Programm in 154 der 444 
Munizipalita¨ten Finnlands 
iFOBT AIHW (2012) 
Australien 
38,5% Aug. 2006 – Juni 2011, 
populationsbezogenes Programm 
iFOBT Zorzi (2012) 
Italien 
48% 2010, bereinigte Teilnahmerate (nur tatsa¨chlich 
eingeladene Personen beru¨cksichtigt), 
populationsbezogenes Programm 
FS Zorzi (2012) 
Italien 
24% 2010, bereinigte Teilnahmerate (nur tatsa¨chlich 
eingeladene Personen beru¨cksichtigt), 
pupulationsbezogenes Programm 
C ZI (2012) 
Deutschland 
18,3% der Ma¨nner
20,1% der Frauen 
kumuliert 2003-2010, 
nicht populationsbezogenes Programm 
RCTs 
gFOBT Hol (2010) 
NL 
49,5% RCT in Vorbereitung auf organisiertes CRC-
Screening Programm in den NL, populationsbe-
zogene Randomisierung, erste Einladungsrunde
iFOBT Hol (2010) 
NL 
61,5% RCT in Vorbereitung auf organisiertes CRC-
Screening Programm in den NL, populationsbe-
zogene Randomisierung, erste Einladungsrunde
iFOBT Van Hal (2011) 
Belgien 
44,3% RCT Pilotstudie fu¨r ev. organisiertes CRC-
Screening Programm in Belgien, populationsbe-
zogene Randomisierung, (52,3% bei Einladung 
per Post, 27,7% bei Einladung u¨ber praktische 
A¨rztin) 
FS Hol (2010) 
NL 
32,4% RCT in Vorbereitung auf organisiertes CRC-
Screening Programm in den NL, populationsbe-
zogene Randomisierung, erste Einladungsrunde
C Stoop (2012) 
NL 
22% RCT in Vorbereitung auf organisiertes CRC-
Screening Programm in den NL, populationsbe-
zogene Randomisierung, erste Einladungsrunde
CT-C Stoop (2012) 
NL 
34% RCT in Vorbereitung auf organisiertes CRC-
Screening Programm in den NL, populationsbe-
zogene Randomisierung, erste Einladungsrunde
C … Koloskopie; CT-C … virtuelle Koloskopie; FS … flexible Sigmoidoskopie , gFOBT … guaiac fecal occult 
blood test; iFOBT immunochemical fecal occult blood test 
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Geschätzte (Einzel-)Testcharakteristika unterschiedlicher Screening-Modalitäten 
Screeningtest Sensitivita¨t (%) 
CRC 
Sensitivita¨t (%) 
Advanced Adenoma
Spezifita¨t (%) 
CRC 
Spezifita¨t (%) 
Advanced  
Adenoma 
gFOBT 11-64 11-41 91-98 n.a. 
iFOBT 56-89 27-56 91-97 n.a. 
Flexible Sigmoidoskopie 60-70 50-81 60-70 50-80 
Koloskopie 95 95 95-99 90-95 
CRC … Colorectalcarcinom; gFOBT … guaiac fecal occult blood test; iFOBT immunochemical fecal occult blood 
test; n.a. … nicht anwendbar 
Quelle: Bretthauer (2011), Tabelle 1 
 
Komplikationen in CRC-Screening-RCTs zu flexibler Sigmoidoskopie: Komplikationen FS 
Studie Perforationen pro 100.000 Blutungen pro 100.000 
Atkin (2010)1 2,48 302 
Segnan (2011) 10 k.A. 
Schoen (2012) 2,8 
2. FS Runde: 107,53 
k.A. 
1 berichtet in: Atkin (2002) 
2 Spitalsaufnahme 
3 author response to letter to the editors: http://www.nejm.org/doi/full/10.1056/NEJMoa1114635#t=letters  
 
Komplikationen in CRC-Screening-RCTs zu flexibler Sigmoidoskopie: Komplikationen Koloskopie nach FS 
Studie Perforationen pro 100.000 Blutungen pro 100.000 
Atkin (2010)1 168 3772 
Segnan (2011) 120 k.A. 
Schoen (2012) 108 k.A. 
1berichtet in: Atkin (2002) 
2 Spitalsaufnahme 
 
Ansätze zur Steigerung der Effektivität 
Das Festlegen einer oberen Altersgrenze für die Teilnahme am Dickdarm-
krebs-Screening wird empfohlen. Ein mehrstufiges Programm, das die ver-
schiedenen AkteurInnen des Screenings und die nachgelagerten diagnosti-
schen, behandlerischen und Surveillance-Prozesse vernetzt, ermöglicht Qua-
litätssicherung, Dokumentation der Ergebnisse und deren Evaluation. Be-
sondere Bedeutung kommt der Gestaltung der dem Screening nachgelager-
ten Surveillance zu. Die dort formulierten Schwellenwerte legen die Anzahl 
der durch Screening induzierten Surveillance-Koloskopien fest. Bei der Ein-
führung eines populationsbezogenen Programms ist ein schrittweises Vor-
gehen, mit gezielter Begleitforschung und Pilottestungen und anschließen-
des schrittweises Ausrollen, wie in den Niederlanden, überlegenswert. 
 
 
Screening-Programm 
soll Vernetzung mit 
Diagnose, Behandlung 
und Surveillance sicher 
stellen 
… schrittweise 
Einfu¨hrung empfohlen 
Zusammenfassung 
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Komponenten der Programmfinanzierung 
Für den nicht unbeträchtlichen Overhead eines qualitätsgesicherten popula-
tionsbezogenen Programms zum Dickdarmkrebs-Screening ist eine nachhal-
tige Finanzierung Voraussetzung. Gleiches gilt für die Finanzierung der ex-
tern programmunabhängigen Bereitstellung von Informationen für poten-
zielle TeilnehmerInnen am Screening, die informed consent über Screening-
Teilnahme oder nicht ermöglichen, und für die Finanzierung der regelmä-
ßigen Evaluation des Programms durch eine externe unabhängige Instituti-
on. 
 
CRC-Screening erfordert 
anfa¨nglich betra¨chtliche 
Nettoinvestition 
… ausreichende 
Finanzierung fu¨r Erfolg 
des Screening-
Programms notwendig 
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1 Introduction 
1.1 Rationale for Colorectal Cancer-
Screening 
Colorectal cancer (CRC) or colorectal adenocarcinoma is a malignant tumor 
arising within the walls of the large intestine, including the segments in the 
cecum, ascending colon, transverse colon, descending colon, sigmoid and 
rectum. CRC does not include tumors in the tissues of the anus or the small 
intestine.1 CRC is common in industrialized countries. In terms of age-
standardized incidence rates, there exists little difference from one Euro-
pean country to another, nor is there a clear geographic pattern.2 Among 
both men and women CRC was the third most common non-skin cancer and 
also the third-highest cause of cancer death in the US in 2009.3 
CRC has a recognizable, protracted pre-malignant stage (adenoma) that is 
relatively easy to remove through polypectomy. If an adenoma has pro-
gressed to carcinoma, it is an average of nearly 7 years before the disease be-
comes symptomatic.4 If CRC is detected early, a person’s chances of survival 
are considerably higher than if it is detected at a later stage: Five-year sur-
vival of CRC exceeds 90% if diagnosed at an early stage (no tumor extension 
beyond the bowel wall). Survival is only about 60% for patients with tumors 
with lymph node involvement and under 10% if metastases are present.5 
Symptoms of CRC develop late in the course of the disease, early detection 
is therefore often not achieved.6 This is why screening for CRC has been in-
troduced in various modes of organization in a number of countries. 
CRC-screening has the potential of both detecting CRC early (as in the case 
of screening for breast-cancer) and (unlike the case of breast cancer) of pre-
vention of CRC, i.e. intervening before a precursor lesion (polyp) becomes 
malignant, by detecting and removing it (through polypectomy).7 
1.2 Background and structure of this report 
The Swiss Cancer League (Krebsliga Schweiz)8 requested a review of the 
secondary literature (health technology assessments, systematic reviews, me-
ta-analyses) on CRC-screening to inform about policy options in this realm. 
(It later commissioned an update in December 2010, the Main Association 
of Austrian Social Security Institutions – Hauptverband der öster-
reichischen Sozialversicherungsträger9 commissioned a second update in 
                                                             
1 USPSTF Whitlock (2008a) p. 2 
2 Health Council of the Netherlands (2009) p. 32 
3 AHRQ Holden (2010) p. 25 
4 Health Council of the Netherlands (2009) p. 77 
5 Bretthauer (2011) citing a review of US cancer statistics. 
6 Bretthauer (2011) 
7 Bretthauer (2011) 
8 www.krebsliga.ch  
9 www.haupverband.at  
burden of colorectal 
cancer (CRC) high 
CRC believed to have 
protracted pre-
malignant stage … 
… can be relatively easy 
removed via 
polypectomy 
(prevention goal of CRC-
screening) 
… early detection of 
CRC raises chance of 
survival (early detection 
goal of CRC-screening) 
review of secondary 
literature on CRC-
Screening for Swiss 
Cancer League … with 
two updates 
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October 2012.) The study questions guiding this report are: 
1. What screening-tests are available for CRC, what are the respective 
test characteristics and what are the respective test’s wider implica-
tion for a CRC-screening program? 
2. What questions and central aspects are to be considered in the con-
text of designing an organized population-based screening-program 
for CRC? 
After the ensuing methods section on the literature search in chapter 2, the 
quality of the three major health technology assessments10 – which are the 
main sources of information this report focuses on – is appraised in chapter 
3. This is done according to the PRISMA-statement on preferred reporting 
items for systematic reviews and meta-analyses.11 Chapter 4 (results part I) 
addresses the first study question and condenses the results of the literature 
review on important facts about CRC-screening. Chapter 5 (results part II) 
addresses the second study question. Part of the focus here lies on distilling 
important questions to ask about CRC-screening and about population-
based screening-program design from the literature. The final chapter 6 
concludes with a brief take-home message from the literature review for de-
signing quality assured population-based CRC-screening programs. 
 
 
                                                             
10 Health Council of the Netherlands (2009), Ontario Health Technology Advisory 
Committee OHTAC (2009), United States Preventive Services Task Force USPSTF 
Whitlock (2008a) 
11 The PRISMA statement: Moher (2009) 
…  on choice of 
screening-test and 
general issues of 
program design 
report  focuses on three 
recent HTAs 
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2 Methods 
2.1 Initial literature search and inclusion 
Dec. 2009 
A systematic search of the literature was conducted on Dec. 22nd 2009 with 
the following PICO12 –question: 
 
“Can (newer) faecal occult blood tests/ colonoscopy/ flexible sigmoidoscopy/ 
CT- or MRT- colonoscopy – virtual colonoscopy – colonography/ capsule 
endoscopy/ DNA-analysis – genetic tests – laboratory tests – biomarker 
alone or in combination detect CRC in asymptomatic adult average risk 
populations early and positively influence the further course of CRC?” 
 
Table 2.1-1: PICO-question for CRC-screening report 
Population healthy adults OR risk groups/ healthy adults with family history in colon cancer 
Interventions 
early diagnosis 
(newer) faecal occult blood tests/FOBT 
colonoscopy 
flexible sigmoidoscopy 
capsule endoscopy 
CT- or MRT- colonoscopy/ virtual colonoscopy/ colonography 
DNA-analysis, genetic tests/testing 
laboratory tests/ biomarker 
Control interven-
tions 
natural history 
placebo 
all interventions see above 
Outcomes 
colon carcinoma mortality 
colon carcinoma, no/less invasive surgery 
screening harm(s) OR adverse outcomes OR adverse advents OR bleeding OR haemor-
rhage OR perforation OR bowel perforation(s) OR procedural complication(s) OR sur-
gery OR admission to hospital OR sedation related event(s) OR chemical colitis OR in-
fection(s) OR death 
Study design only HTA, systematic reviews, meta-analysis 1999-2009 
 
The search was limited to secondary literature (health technology assess-
ments, systematic reviews, meta-analyses) published from 1999-2009. The 
following databases were searched: 
Primary Databases: HTA, DARE, EED, Cochrane (NICE, CADTH, 
AHRQ, DIMDI), EuroScan 
Secondary Databases: Medline, EmBase 
                                                             
12 PICO: Patient, Population or Problem / Intervention or exposure / Comparison In-
tervention/ Outcome 
PICO question for 
literature search 
 
Systematic search 
limited to secondary 
literature published 
from 1999-2009 
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This systematic search yielded 242 results. When three recent and reliable 
HTA-reviews (Health Council of the Netherlands 2009, Ontario Health 
Technology Advisory Committee OHTAC 2009, United States Preventive 
Services Task Force USPSTF 2008a – marked in bold in list of references at 
the end of the report) were identified, covering the evidence at least until the 
end of 2007, the search was narrowed to sources published thereafter, i.e. in 
2008, 2009. Of the initial 242 results 33 remained. Of these 2 articles were 
duplicates, after their removal 31 articles remained 
The abstracts of these 31 articles were reviewed independently by two re-
searchers. Disagreements about inclusion were resolved through discussion 
and consensus. 18 articles were excluded on the basis of their abstracts as 
not relevant for the PICO-question of this report. 13 articles were included 
in the analysis for this report. These 13 references are marked “[SS-2009]” – 
for systematic search in Dec. 2009 – in the list of references at the end of this 
report. 
Due to a special interest in recent developments in the field of molecular 
screening-tests expressed by the Swiss Cancer League (Krebsliga Schweiz), 
the above systematic search for secondary literature was supplemented by a 
small, unsystematic search for primary literature on new molecular screen-
ing-tests: 
 Medline: Gen*tests OR Biomarker AND Colon Cancer AND Screen-
ing; limits: RCT, CT 
 Google: “Gentest” and the above 
This unsystematic search yielded 3 articles, all of which were included. 
These 3 references are marked “[MOHS-2009]” – for molecular hand search 
in Dec. 2009 – in the list of references at the end of this report. 
Both searches were supplemented with a hand search for topic specific pri-
mary articles informing on details of issues covered in this report, yielding 
38 references- The 25 references used for this report are marked “[BG-
2009]” – for background 2009 – in the list of references at the end of this re-
port. The remaing 13 references not used in this report can be found in ap-
pendix B together with a brief description of their content. 
In the course of the compilation of this report further references were in-
cluded. 
2.2 Update literature search and inclusion 
Nov. 2010 
Following a request from the Swiss Cancer League (Krebsliga Schweiz) an 
update search of the literature was conducted on Nov. 12th 2010 adhering to 
the procedure detailed above. 
This systematic update search yielded 46 results that were published in 2009 
and 2010 and had not been included in the results of the initial literature 
search in December of 2009. 
The abstracts of these 46 articles were reviewed – this time by only one re-
searcher. 43 were excluded on the basis of their abstracts as not relevant for 
the PICO-question of this report. 3 results were included in the analysis for 
after high-quality HTAs 
from 2008 and 2009 
were identified, search 
was narrowed to articles 
published thereafter 
(2008, 2009) 
systematic search 
produced 13 articles 
additional unsystematic 
search on new 
molecular screening-
tests produced 3 articles 
hand search produced 
an additional 38 
relevant articles 
update search with 
identical PICO question 
in Nov. 2010 
systematic update 
search produced 3 
relevant articles 
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this report. These 3 references are marked “[SS-2010]” – for systematic 
search in Nov. 2010 –in the list of references at the end of this report. Among 
these three references was a publication by the Canadian Agency for Drugs 
and Technologies in Health on the next generation of fecal DNA tests13. 
This reference addresses the special interest in recent developments in the 
field of molecular screening-tests expressed by the Swiss Cancer League 
(Krebsliga Schweiz). 
In the course of the compilation of the 2010-update of the report a further 8 
topic specific primary and secondary articles – identified by a hand search – 
informing on details of issues covered in this report were included. To dif-
ferentiate these articles in the reference list at the end of this report they 
were marked “[BG-2010]” – for background 2010. The most important of 
these was the publication of results of a multicentre randomized controlled 
trial on once-only flexible sigmoidoscopy screening from the UK.14 
2.3 Second update literature search and 
inclusion Aug. 2012 
Following a request from the Main Association of Austrian Social Security 
Institutions (Hauptverband der österreichischen Sozialversicherungsträger) 
a second update search of the literature was conducted on Aug. 8th 2012 ad-
hering to the procedure detailed above. The focus was on recent evidence 
about recommended CRC-screening tests (FOBT, flexible sigmoidoscopy, 
colonoscopy). 
This systematic update search yielded 469 results that were published in 
2010-2012. This large number of results compared to the two previous 
searches underlines the importance CRC-screening enjoys as a dynamic re-
search field at present. No new HTA-reports were identified. 
The abstracts of these articles were reviewed by two researchers independ-
ently. Disagreements about inclusion were resolved through discussion and 
consensus. 460 results were excluded as not relevant for the PICO-question 
of this report with the focus of this update in mind. 9 results were included 
in the analysis for this report. Two of these references15 had already been 
identified in the previous systematic update search from Nov. 2010, which 
partly overlapped for publications from 2010. This way 8 new references re-
mained and are marked “[SS-2012]” – for systematic search in Aug. 2012 – 
in the list of references at the end of this report.  
In the course of the compilation of the 2012-update of the report a further 20 
topic specific primary and secondary articles – identified by a hand search – 
informing on details of issues covered in this report were included. To dif-
ferentiate these articles in the reference list at the end of this report they 
were marked “[BG-2012]” – for background 2012. 
 
                                                             
13 Morrison, A. Next-generation fecal DNA tests – an evolving technology [Environ-
mental Scan issue 7]. Ottawa: Canadian Agency for Drugs and Technolgies in 
Health; 2010 
14 Atkin (2010) 
15 Atkin (2010), Spada (2010) 
hand search produced 
an additional 8 relevant 
articles 
second update search 
with identical PICO 
question in Aug. 2012 
systematic update 
search produced 7 new 
relevant articles 
hand search produced 
an additional 20 
relevant articles 

 LBI-HTA | 2012 23 
3 Appraisal of three core HTAs 
The core of this report is based on three health technology assessments/ sys-
tematic reviews on the broader issue of CRC-screening by major health 
technology assessment or related institutions: Health Council of the Nether-
lands16, United States Preventive Services Task Force17 and Ontario Health 
Technology Advisory Committee18. The three publications were identified 
in the initial systematic search of the literature for this report in Dec. 2009. 
The systematic update searches in Nov. 2010 and Aug. 2012 did not identify 
additional health technology assessments/ systematic reviews with this 
broad scope. The three publications are appraised according to the PRIS-
MA-statement on preferred reporting items for systematic reviews and meta-
analyses in table 3-1 below.19 
These three HTAs and additional relevant health technology assessments on 
narrower aspects within CRC-screening are listed in appendix A. 
 
 
 
                                                             
16 Health Council of the Netherlands (2009) 
17 United States Preventive Services Task Force USPSTF Whitlock (2008a) 
18 Ontario Health Technology Advisory Committee OHTAC (2009) 
19 The PRISMA statement: Moher (2009), table 1, p. 266 
3 HTAs by Health 
Council of the 
Netherlands, USPSTF, 
Ontario HTAC form the 
core of report 
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Table 3-1: Appraisal of three core HTAs relied on for this report 
Institution Study Quality Appraisal 
PRISMA for SRs and MAs 
Comment 
Health Council of the 
Netherlands (2009) 
PRISMA checklist mostly not fulfilled 
as report is not published as system-
atic review 
This advisory report to the Dutch Minister of Health, Welfare and Sport on whether and if, how to implement a na-
tional screening program is based on extensive literature and thorough evaluation of it. While not technically published 
as a systematic review, the results and discussion sections are similar. The additional value of this report is the explicit 
program focus and the incorporation of data from several pilot programs specifically undertaken to inform the decision 
making process in the Netherlands. 
 
Publication bias was not assessed. 
Ontario Health Tech-
nology Advisory 
Committee  
OHTAC (2009) 
PRISMA checklist fulfilled except: 
section 1: report declared as “evi-
dence based analysis” not as “system-
atic review” 
section 2: structured abstract com-
pletely lacking 
section 12, 15, 19, 22: risk of bias in 
and across studies not extensively 
addressed 
point 27: role of funder in process of 
review not detailed 
 
United States Preven-
tive Services Task 
Force  
USPSTF 
(2008 und 2008a) 
PRISMA checklist fulfilled except sec-
tion 12, 15, 19, 22 (risk of bias in and 
across studies) – compare comment 
The review question was clear and supported by detailed inclusion criteria which are potentially reproducible. The 
search strategy included some relevant sources for published studies, but there was no apparent attempt to locate un-
published material. Publication bias was not assessed. Appropriate validity assessment tools were used to assess the 
quality of effectiveness and diagnostic studies. However, the results of this were not given in detail, making it difficult 
to verify the reported global assessment. The reported review process demonstrated attempts to minimize errors and 
bias. Heterogeneity was taken into account in the proposed methods of synthesis. The authors' conclusions reflected the 
results from a small number of included studies. The conclusions are probably reliable, but under reporting in relation to 
study quality may warrant a cautious interpretation.20 
 
 
                                                             
20 from Database of Abstracts of Reviews of Effects (DARE), produced by the Centre for Reviews and Dissemination, University of York 
www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008106882 – accessed March 14th 2010 
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4 Results part I: Facts about colorectal  
cancer-screening 
4.1 Colorectal cancer 
It is believed that the vast majority of CRC develops from benign precursor 
lesions (adenomatous polyps or adenomas) through a series of genetic 
changes over a long-time period.21 It is estimated that only 5% of all adeno-
mas actually become malignant. The removal of these 5% of adenomas is 
sufficient to prevent CRC. The problem is that it is impossible to know 
which adenomas will become malignant and which will not. This inevitably 
results in a degree of over-diagnosis.22 In the case of most adenomas, remov-
ing them would have no effect on the survival of the individual concerned. 
The rates of over-diagnosis liable to result from CRC-screening cannot cur-
rently be quantified accurately.23 
Most CRC develops in average risk individuals, patients (approximately 75-
80% or more) who have no close relatives with this disease. This majority of 
cases are classified as ‘sporadic CRC’.24 
Approximately 20% of patients with CRC have some type of family history 
of CRC. For family-history CRC the lifetime risk of developing CRC de-
pends on the number of relatives with this cancer, their degree of kinship 
and the age at which CRC was diagnosed.25 Hereditary, genetically deter-
mined forms of CRC, i.e. Lynch syndrome – until recently referred to as he-
reditary non-polyposis colorectal carcinoma – and the various forms of poly-
posis are predisposed by genetical mutation and account for approximately 
5% of all cases of CRC.26 Individuals with Lynch syndrome are germ-line 
mutation carriers. They have a 25-70% lifetime risk of CRC. In people suf-
fering from familial adenomatous polyposis that risk is virtually 100 %.27 
For these hereditary, genetically determined forms of CRC-syndromes the 
issues involved in identifying candidates at risk, genetic testing, diagnosis 
and management are different than in general CRC-screening of average 
risk populations.28 
The remainder of CRC-cases develops in persons who have predisposing in-
flammatory bowel disease.29 
                                                             
21 Bretthauer (2011) p. 87 
22 Health Council of the Netherlands (2009) p. 32 
23 Health Council of the Netherlands (2009) p. 80 
24 USPSTF Whitlock (2008a) p. 3, Health Council of the Netherlands (2009) p. 34, 
Bretthauer (2011) p. 87 
25 Health Council of the Netherlands (2009) p. 34, Baglietto (2006), Butterworth 
(2006) 
26 Lynch (2003), Hampel (2005), USPSTF Whitlock (2008a) p. 3 
27 Health Council of the Netherlands (2009) p. 35 
28 e.g. Lynch (2009) 
29 USPSTF Whitlock (2008a) p. 3 
cancer-screening by 
definition results in over 
diagnosis … 
… degree difficult to 
quantify for CRC 
80% of CRC sporadic  
20% have family history 
of CRC … 
… these are not target 
of general screening: 
5% hereditary CRC with 
25-100% lifetime-risk of 
developing CRC 
90% of newly 
diagnosed CRC-patients 
over 55 years … 
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More than 90% of all new CRC-patients were above 55 years of age in 
2009.30 Age and gender are the only effective risk factors in risk profiling 
prior to CRC-screening. The research literature contains reports of various 
attempts to develop a model for risk profiling. As yet, however, there are no 
usable, validated examples.31 
4.2 Polyp size and CRC-screening 
A colorectal polyp is a fleshy growth occurring on the lining of the colon or 
rectum. A subtype of polyps are adenomas, benign tumors of glandular ori-
gin. Adenomas can grow from many organs including the colon.32 
Without the benefit of biopsy results, referral to colonoscopy is based on 
polyp size. Referral thresholds of screen-detected lesions to colonoscopy are 
largely based on expert opinion rather than clinical outcomes.33 
Polyp size < 6mm: 80% of found abnormalities 
 consensus by most, but not all experts34: no referral required 
 risk of being malignant in screening-population 0.03-0.2% 
Polyp size 6-10 mm: small polyps 
 no consensus; necessity and benefit of removing small polyps is not 
clear35 
 data from large screening-studies: 3 – 9% are advanced neoplasia 
(composite outcome: adenocarcinoma/ invasive carcinoma/ CRC and 
advanced adenoma36) 
 there have been no prospective studies describing the natural his-
tory of advanced neoplasia, and no longitudinal studies have vali-
dated the clinical benefit of targeting advanced neoplasia in screen-
ing-populations37 
 On the basis of data on the natural course of small polyps, there is no 
reason why a “wait-and-see policy” should not be adopted. For in-
stance, a study involving the annual endoscopic surveillance of ‘small’ 
polyps found that, after 3 years, their average diameter even tended to 
decline slightly.38 
 
                                                             
30 data for the Netherlands as example, Health Council of the Netherlands (2009) p. 
33 
31 Health Council of the Netherlands (2009) p. 37 
An example for an area in which the evidence base is evolving would be the ques-
tion if to suggest different screening-age limits for women and men. 
32 compare: www.wikipedia.org  
33 USPSTF Whitlock (2008) 
34 USPSTF Whitlock (2008) 
35 USPSTF Whitlock (2008a) p. 4 
36 e.g. USPSTF Whitlock (2008a) p. 2 
37 USPSTF Whitlock (2008a) p.6 
38 Hofstad (1996) cited in Health Council of the Netherlands (2009) p. 70 
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Polyp size >10mm: large polyps  
 consensus: should be removed 
 10-15% probability of being or becoming malignant 
 evidence that removal of large adenomas has a particularly marked 
impact on the incidence of CRC39 (caveat! – data on the reduction of 
CRC-incidence through colonoscopy and polypectomy rely on weak 
evidence40) 
Unanswered questions remain about the natural history of adenomas under 
10mm and therefore about their clinical significance. Clarifying the risk as-
sociated with smaller polyps will be critical for estimating the true sensitiv-
ity and specificity of current and future CRC-screening methods that di-
rectly visualize lesions. 
Treatment costs for highly advanced stages of CRC (i.e. the very cases that 
screening can often prevent) are expected to rise sharply when the latest very 
expensive generation of chemotherapy agents is deployed. This increase in 
the cost of CRC treatment makes screening for CRC more cost-effective.41 
4.3 CRC-screening trials 
Measuring the outcome of CRC-screening trials 
Screening aims to save lives, i.e. screening strives to reduce all-cause mortal-
ity. There are three commonly used measures for evaluating the impact of 
CRC-screening on a population’s health: ‘all-cause mortality’ directly and its 
surrogates, ‘disease-specific mortality’ and ‘detection rate’ – detection of ad-
vanced adenomas’ or more narrowly ‘detection of CRC’. 
The optimal outcome measure for screening-trials is all-cause mortality. Da-
ta on all-cause mortality is reliably and readily available. This endpoint re-
quires very large samples, though. Of all causes of death, CRC represents 
very roughly 3%, a small fraction.42 The best available evidence suggests 
that the effect size of CRC-screening is a 15% reduction of CRC-mortality.43 
Even if directly translated into a reduction of all-cause mortality, assuming 
CRC-screening would not induce additional mortality, the effect of CRC- 
screening would represent only approximately 0.45% of all-cause mortality, 
a very small effect size to prove in a randomized controlled trial. When, as 
in this case, the disease-specific mortality is proportionally very low, only a 
very slight increase in non-cancer mortality is required to offset a reduction 
in cancer mortality and vice versa.44 As a result the necessary sample size to 
                                                             
39 Health Council of the Netherlands (2009) p. 80 
40 USPSTF Whitlock (2008a) p. 4 
41 Health Council of the Netherlands (2009) p. 51 A debate in cost-effectiveness re-
search concerns which costs to include in evaluations. If lost productivity through 
CRC were to be incorporated, which is at present not state of the art, cost-
effectiveness of CRC-screening would become more favorable. 
42 US CRC-lifetime mortality rate 2.4%, females 3.3%, USPSTF Whitlock (2008a) 
43 Cochrane Systematic Review, Hewitson (2007) 
44 Black (2002) 
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give a study sufficient power would have to be 300,000 per group in the case 
of CRC-screening.45 Studies of all-cause mortality that are sufficiently large 
to have the required precision would not be feasible in many situations.46 
Since screening trials are expensive, require long follow-up and can include 
only a few comparison tests, validated microsimulation models may be used 
as an additional source of information for policy makers.47 This leads to an 
unresolved dilemma: Presently there is no evidence from randomized con-
trolled trials showing a reduction of all-cause mortality through CRC-
screening. This lack of high-grade evidence leads to two interpretations: On 
one side the lack of high-grade evidence may suggest caution about CRC-
screening. On the other side the fear is expressed, that a number of truly ef-
fective cancer-screening tests will incorrectly be deemed ineffective if em-
phasis is given to all-cause mortality, because it is not generally feasible to 
do studies that are large enough to reliably document the impact of screen-
ing on all-cause mortality.48 
It has been assumed that disease-specific mortality is a good surrogate end 
point for all-cause mortality. Because fewer patients are required for a study 
to provide adequate power, disease-specific mortality rather than all-cause 
mortality has been the accepted end point of screening-studies. Disease-
specific mortality data are obtained via the cause-of-death statistics. These 
are less reliable than death statistics because of attribution problems of 
cause of death in practice. Even if disease-specific mortality is used for rea-
sons of pragmatism, a decrease in all-cause mortality should be the ultimate 
aim of screening-programs, whether measured directly or not. A death from 
a non-malignant cause is just as important as a cancer-related death.49 
Biases in screening trials 
A concept from cancer screening epidemiology that is relevant for interpret-
ing the results of screening trials is “lead time”. Lead time is the interval 
from diagnosis of a screening detected cancer to the the point in time when 
cancer would have been diagnosed without screening. In the case that the 
patient dies from CRC at the same time regardless if the cancer was detected 
early through screening or later, lead time bias would result in survival es-
timates favouring screening, because the cancer is detected earlier than 
without screening (even though in this case screening did not provide any 
survival benefit).50 
A problematic bias in screening-studies is the so called “slippery linkage bi-
as”.51 Screening-activity and cancer treatment can be associated with excess 
non-cancer mortality (e.g. car accidents after sedation for screening-
colonoscopy, stroke during colonoscopy, heart attack during CRC-surgery). 
If these deaths are not accurately linked to cancer-screening and cancer 
treatment, if “the link slips”, a cancer-screening or cancer treatment-
induced death is not recorded under disease-specific mortality and conse-
quently makes screening or cancer-treatment appear more beneficial than it 
actually is. 
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Where studies are too small (in terms of number of participants and/ or 
length of follow-up) to detect CRC-screening impact on disease-specific 
mortality, it is often necessary to use even weaker intermediate end points to 
approximate the desired screening-outcome of reduced all-cause mortality. 
In the case of CRC-screening these intermediate endpoints are ‘detection of 
advanced adenomas’ and ‘detection of CRC’. These two measures are often 
combined and referred to as ‘detection of advanced neoplasia’. The assump-
tion would be that higher detection of advanced neoplasia translates into 
lower CRC-mortality. That is not always grounded in fact, as by no means 
all advanced adenomas become malignant. In the case of most adenomas, 
removing them would have no effect on the survival of the individual con-
cerned. Including all advanced adenomas as relevant screening-yield causes 
the effect of screening to be overestimated. At the other end of the disease 
spectrum, late stage CRC is also included as relevant yield, while only a 
small number of such cases can be cured. This too tends to overestimate the 
effect of screening. The goal of screening is not simply to detect abnormali-
ties, it is to reduce people’s risk of developing CRC and of dying from this 
disease.52 
The introduction phase of a population based CRC-screening program is 
suggested as a setting for evidence generation at relatively little additional 
cost compared to setting up large clinical trials. Screening for CRC using 
any primary test modality is suggested to be launched in a public health 
program with randomization of the target population at the implementation 
phase. This experimental design is considered to be a prerequisite for evalu-
ation of such a screening-program because the effectiveness of preventing 
deaths is likely to be small and results may otherwise remain inconclusive.53 
Establishing the net-effect of screening healthy people – only a few of whom 
can be helped, some of whom will be harmed, and most of whom will experi-
ence little effect – will often exceed the limits of medical science. Thus there 
is all the more reason for full disclosure of both what is known and what is 
unknown about screening for informed decision making.54 
Need for screening-trials to be population based 
Screening needs to be effective in the general population at average risk for a 
disease. Ideally screening studies recruit individuals directly from the popu-
lation registry. In this case they are population based. For the pragmatic rea-
son of increasing the power of a study, two step recruiting processes are used 
in screening studies. The first step could be a questionnaire asking about 
general willingness to participate in screening if offered, like, for example, 
in two large recent studies on flexible sigmoidoscopy screening that in-
cluded only such individuals.55 Apart from the general problem of self-
selection bias of recruited subjects (subjects may show a different risk pro-
file compared with the general population)56, self selection in screening tri-
als on the basis of the important parameter of “willingness to participate in 
screening” will inflate the important parameter of participation rate above 
the levels realistic for population based screening. Such studies provide es-
                                                             
52 Health Council of the Netherlands (2009) p. 32 
53 Malila (2008) 
54 Black (2002) 
55 Atkin (2010), Segnan (2011) 
56 Segnan (2011) 
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timates of the efficacy of screening, but the effectiveness of screening in the 
general population remains uncertain.57 
Intention-to-screen vs. per-protocol analysis of screening trials 
The equivalent of intention-to-treat analysis in clinical trials is intention-to-
screen analysis in screening trials. Non compliance in the screening group is 
thereby taken into account: non participation in screening, non participa-
tion in follow-up colonoscopy in case of positive first-line screening test, non 
participation in one or more subsequent screening round(s). Supposing a 
positive effect of screening on disease specific mortality and cancer inci-
dence, intention-to-screen analysis will result in weaker effects on relative 
risk, since the non participants in screening are included. The results of in-
tention-to-screen analysis are relevant for public health decision makers, 
since non participation of screening is a fact of life. Per-protocol analysis of 
screening trials provides estimates of risk reductions for those individuals 
who attend screening. This information is relevant for an individual member 
of the general population at average risk who contemplates if or if not to at-
tend screening. An example of the different results of intention-to-screen 
(public health perspective) and per-protocol analysis (perspective of the in-
dividual contemplating screening) from meta-analysis of the four gFOBT 
screening trials is: 16% reduction of CRC-mortality in intention-to-screen 
analysis, 25% reduction of CRC-mortality for those individuals who attend-
eded at least one round of screening.58 
Evidence required for introduction of new screening-test 
What is the situation when new tests emerge, while a screening-test that has 
been proven to be effective (such as gFOBT59) is already available? Guide-
lines for such situations have been drawn up on the basis of systematic re-
views of the literature together with a consensus approach involving experts. 
Studies to determine whether a new test is as good as or better than existing 
ones do not need to use disease-specific mortality as an end point again, pro-
vided that randomized screening-trials have demonstrated that the existing 
test reduces disease-specific mortality. The evaluation must involve a direct 
comparison of the old and new tests on the basis of ‘intention to screen’, a 
comparison in terms of uptake and yield, the evaluation must be conducted 
among the general population and followed by a cost-effectiveness analy-
sis.60 
 
                                                             
57 Bretthauer (2011) 
58 compare Bretthauer (2011) 
59 Cochrane Systematic Review, Hewitson (2007) 
60 Health Council of the Netherlands (2009) p. 28 
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4.4 Colonoscopy in CRC-screening 
In contrast to the situation with most other screen-able diseases, there are 
several (first-line) screening-tests available for CRC: FOBTs, flexible sig-
moidoscopy and colonoscopy, to name the strategies recommended by the 
USPSTF. The methods differ in various ways. Very important is their im-
pact on participation and as a result program sensitivity/ specificity. Colon-
oscopy is the final common (second-line) test of all CRC-screening strate-
gies. Figure 4.4-1 illustrates the central role of colonoscopy in CRC-
screening. 
Figure 4.4-1: Colonoscopy as the final common pathway for CRC-screening 
 
 
 
several first-line tests 
exist – colonoscopy as 
final common screening-
pathway 
*in practice CT-colonography is presently not recommended by any mayor health-
technology-assessment institution or medical society as a first-line test for popu-
lation-based CRC-screening 
Abbreviations: CT-C … computed tomography colonography 
 FOBT … faecal occult blood test 
 FS … flexible sigmoidoscopy 
Source: adapted from figure 1, Health Council of the Netherlands (2009) p. 13 
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4.5 Evidence on CRC-screening tests 
The evidence base from large trials on the effectiveness of different first-line 
screening tests for CRC is limited. There is no evidence on the effect of 
CRC-screening on all-cause mortality. So far gFOBT and FS have been 
proven to reduce CRC-mortality in screening-trials. Confidence interval 
values of gFOBT and FS effects overlap, so the superiority of one test over 
the other cannot be determined.61 No head-to-head trials comparing FOBT 
and FS have been conducted62, nor are any ongoing. First evidence on 
iFOBT and C is another decade away. 
 guaiac faecal occult blood test or gFOBT: 4 randomized controlled 
trials (RCTs). Three trials used repetitive multiple screening rounds, 
either annually or bi-annually, one trial offered two rounds of screen-
ing only with a two year interval, three trials were population based, 
one trial enrolled subjects only after they had agreed to participate in 
screening. Participation was between 53-78%, 78% in the trial enroll-
ing subjects only after agreeing to participate in screening.63 Disease-
specific CRC mortality: relative risk reduction (RRR) 15%, no impact 
on all-cause mortality64. For trial results on gFOBT compare table 
4.7-1 below. 
 immunochemical faecal occult blood test or iFOBT: none65. 1 Spanish 
RCT comparing C and biennial iFOBT completed first round of 
screening66 - results expected in 2021, 1 US-RCT comparing C and 
iFOBT in recruiting phase – results expected in 202567 
 biomarkers other than blood markers: none 
                                                             
61 Bretthauer (2011) 
62 Bretthauer (2011) 
63 Bretthauer (2011) 
64 Compared to no screening in an intention-to-screen analysis, taking into account 
non-complicance in the screening group. A 25% risk reduction was observed for 
those individuals who attended at least one screening round (RR 0.75, 95% CI 0,66-
0.84), compare Bretthauer (2011) and Cochrane Systematic Review, Hewitson 
(2007). 
65 One RCT from Jiashan County, China, published in 2003 with only one round of 
iFOBT-screening is difficult to interpret, compare Bretthauer (2011). 
66 Barcelona, Spain, COLONPREV-study: Colorectal cancer screening in average-risk 
population: immunochemical fecal occult blood test versus colonoscopy, ten years 
of follow-up. Results at completion of baseline screening published in Quintero 
(2012), population-based participation rate iFOBT 34.2%, C 24.6%. 
Trial registered at www.ClinicalTrials.gov with registration no: NCT00906997 
67 US, Department of Veterans Affairs, CONFIRM-study. Colorectal cancer screen-
ing in average risk Veterans Affairs population: annual quantitative immuno-
chemical fecal occult blood testing versus colonoscopy, enrolment of 50,000 
planned, ten years of follow-up. 
Trial registered at www.ClinicalTrials.gov with registration no: NCT01239082 
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 colonoscopy: none.68 1 RCT69 completed completed first round of 
screening, 2 RCTs70 in recruiting phase, – results in 10+ years 
 flexible sigmoidoscopy: 3 non population based RCTs, two once only, 
one two FS rounds, reportet participation rates of 71%, 58%, 86% and 
disease-specific RRR of 33%,(statistically not significant) 22%, 26% 
and no impact on all-cause mortality. For more detailed trial results 
on flexible sigmoidoscopy compare table 4.7-5 below. 
 CT-colonoscopy: none. 1 Spanish RCT comparing C and biennial 
iFOBT completed first round of screening71 - results expected in 
2021, 1 US-RCT comparing C and iFOBT in recruiting phase – re-
sults expected in 202572 
 
 “Randomized trials have been a long-standing requirement for the intro-
duction of new drugs to the market. It is difficult to understand why the 
standard of evidence should be lower for diagnostic tools or screening 
tests.”73 
                                                             
68 Church (2011) cites a nested case-control analysis of colonoscopy utilization and 
CRC outcomes in Canada by Baxter (2009) as estimating a rather similar effect of 
colonoscopy screening on CRC mortality as of screening with flexible sigmoido-
scopy and gFOBT. 
69 Barcelona, Spain, COLONPREV-study: Colorectal cancer screening in average-risk 
population: immunochemical fecal occult blood test versus colonoscopy, ten years 
of follow-up. Results at completion of baseline screening published in Quintero 
(2012). 
70 Nordic countries, the Netherlands and Poland, NordICC-study. Once only colono-
scopy. 
Trial is registered at www.ClinicalTrials.gov with registration no: NCT0088379 
US, Department of Veterans Affairs, CONFIRM-study. Colorectal cancer screening 
in average risk Veterans Affairs population: annual quantitative immunochemical 
fecal occult blood testing versus colonoscopy, enrolment of 50,000 planned, ten 
years of follow-up. 
Trial registered at www.ClinicalTrials.gov with registration no: NCT01239082 
71 Barcelona, Spain, COLONPREV-study: Colorectal cancer screening in average-risk 
population: immunochemical fecal occult blood test versus colonoscopy, ten years 
of follow-up. Results at completion of baseline screening published in Quintero 
(2012), population-based participation rate iFOBT 34.2%, C 24.6%. 
Trial registered at www.ClinicalTrials.gov with registration no: NCT00906997 
72 US, Department of Veterans Affairs, CONFIRM-study. Colorectal cancer screen-
ing in average risk Veterans Affairs population: annual quantitative immuno-
chemical fecal occult blood testing versus colonoscopy, enrolment of 50,000 
planned, ten years of follow-up. 
Trial registered at www.ClinicalTrials.gov with registration no: NCT01239082 
73 Betthauer (2009) p. 301 
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4.6 Characteristics of Colonoscopy in CRC-
screening 
Because of the central role of colonoscopy in CRC-screening its characteris-
tics are elaborated on first. Characteristics of other screening tests and over-
view tables of all screening tests’ characteristics can be found in chapter 4.7. 
In colonoscopy, a video-endoscope is used to examine the entire length of 
the colon. Extensive bowel preparation is required. Colonoscopy is often 
performed with the subject under conscious sedation. Depending on the re-
gionally established clinical practice, operator preference and setting (pri-
vate practice, hospital) colonoscopy is also performed without sedation. In 
France, for example, most colonoscopies are performed under full sedation, 
requiring the presence of an anaesthesiologist.74 Colonoscopy is considered 
the (imperfect) reference standard for detecting CRC and adenomas. Where 
technically possible, polyps are removed immediately (polypectomy). If this 
is not possible, biopsies are taken. All retrieved lesions are evaluated his-
tologically. In this respect colonoscopy stands out in potentially being at 
once a screening (optical inspection), diagnostic (biopsy) and therapeutic in-
tervention (polypectomy) covering the entire colon. Flexible sigmoidoscopy 
only covers the left (distal) colon with these functions. Some screening-
programs use colonoscopy as a first-line screening-method. With all screen-
ing-methods, if any abnormalities are detected, the patient is referred for co-
lonoscopy. Colonoscopy is the final common pathway of all CRC-screening. 
With advancing age and coexisting conditions the risk associated with co-
lonoscopy increases. At the same time the benefit diminishes because of 
shorter life expectancy.75 This is the rationale behind setting upper age lim-
its for CRC-screening.76 
Two aspects limit colonoscopy as a perfect gold standard for CRC and ade-
noma detection. Endoscopic methods are operator and technology depend-
ent.77 Accuracy is highly dependent on the quality of the bowel preparation 
and endoscopic examination.78 Inter-examiner differences in detection of 
polyps have been shown in population-based studies of screening-
colonoscopy.79 The examiners’ skill and care in examining the colon (com-
pleteness of colonoscopy, withdrawal time) vary greatly. Repeated colono-
scopy or colonography by means of computed tomography performed in 
close succession to colonoscopy can identify neoplastic lesions that were not 
detected during the initial procedure.80 These important missed lesions in-
clude adenomas greater than 10 mm in diameter.81 Both polyp-yield82 and 
complication rate83 vary by a factor of up to ten between examiners. 
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CRC-screening stands out from screening for other diseases. Although co-
lonoscopy is generally safe, it is an invasive procedure with a 0.2% rate of se-
rious complications — ten times higher than for any other commonly used 
cancer screening test. Repeated examinations over time may incur a sub-
stantial cumulative rate of complications, not counting hard-to-detect com-
plications (if they occur), such as silent myocardial infarction.84 Complica-
tions of colonoscopy increase with age and have declined overall85, perhaps 
due to an increased focus on quality and because of developments in endo-
scopic technology. No other screening-test – e.g. PAP for cervical cancer and 
mammography for breast-cancer – has comparable rates to colonoscopy of 
serious adverse complications, including death, through the testing itself. In 
this sense colonoscopy is unprecedented for a screening-test recommended 
for use in the general population.86 
The evidence on complication rates after screening-colonoscopy compared to 
symptomatic colonoscopy is inconclusive and evolving. On the one hand 
some of it suggests that complication rates of screening-colonoscopies are 
lower than of diagnostic and therapeutic colonoscopies performed in symp-
tomatic patients.87 The argument here would be that individuals participat-
ing in screening are on average younger and in better health than sympto-
matic patients. On the other hand recent research finds complications after 
colonoscopies two to three times higher than previously estimated, and more 
complications happening after screening colonoscopy than after sympto-
matic colonoscopy.88 Risks of complications reported in organized screening 
programs are lower than those reported for general practice colonoscopies.89 
Procedure related hospital visits within 14 days of the procedure occurred in 
0.84% of colonoscopies and in 0.95% of screening colonoscopies. Most events 
were not captured by standard reporting. The complication rate might in re-
ality be higher since only complications treated at the studied hospital were 
recorded and not in neighbouring ones. The most common complications 
were abdominal pain (47%), gastrointestinal bleedings (12%) and chest pain 
(11%). The cost of unexpected hospital visits post endoscopy may be signifi-
cant and should be taken into account in screening and surveillance pro-
grams. Also strategies for automating adverse event reporting should be de-
veloped. 
A systematic review of perforation and mortality of colonoscopy found no 
differences in complication rates between screened populations versus pa-
tient populations:90 The overall perforation rate of colonoscopy (higher for 
colonoscopies with polypectomy than for those without) was 66 per 100,000 
and the overall mortality rate 6 per 100,000. 
For more information on colonoscopy as a first-line screening-test compare 
table 4.7-4 below. 
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Though evidence on the magnitude of overall protection from CRC accord-
ing to anatomical site through colonoscopy performed in the community set-
ting is sparse, the association of colonoscopy with fewer deaths from CRC is 
primarily limited to deaths from cancer developing in the left side of the co-
lon (distal cancer).91 There is evidence from Germany, Canada and the US 
that colonoscopy is less effective for right-sided (proximal) CRC than for left 
sided (distal) CRC.92 There is evidence that the prevalence of left-sided (dis-
tal) but not of right-sided (proximal) advanced adenomas is reduced within 
a 10-year period after colonoscopy.93 Why would colonoscopy be less effec-
tive in preventing death from right-sided (proximal) CRC? The evidence 
base on which to answer this question is still evolving, possible reasons are: 
First, some supposedly “complete” colonoscopies in practice do not actually 
evaluate the entire right (proximal) colon all the way to the cecum. Second, 
bowel preparation may be worse in the right (proximal) colon. Finally, right-
sided (proximal) and left-sided (distal) colonic neoplasia may differ biologi-
cally. Right-sided (proximal) colonic adenomas are less often pedunculated 
and are occasionally flat, which makes them harder to identify and remove. 
The histology and molecular features of right-sided (proximal) cancer may 
differ, implying predominant genetic pathways of carcinogenesis, which may 
influence the effectiveness of early detection. Differences in tumor biology 
may limit the potential to prevent right-sided (proximal) CRC-death with 
current endoscopic technology.94 Data from the US demonstrate a right-
sided (proximal) migration of CRC over the past two decades, which is at-
tributed to a decrease in incidence of left-sided (distal) CRC and an aging 
population in which right-sided (proximal) lesions are more common.95 
Estimating the sensitivity and specificity for screening-colonoscopy in a real 
life environment from the available evidence is even more challenging than 
for diagnostic colonoscopy, where the data situation is better. Most available 
studies for screening-colonoscopies have selected practitioners who were 
quite experienced and not necessarily representative of community practice. 
No tandem colonoscopy studies evaluated average-risk populations.96 
Randomized trials studying the effect of colonoscopy on the incidence of or 
the mortality due to colorectal cancer have not been conducted. Two are un-
derway, though, comparing colonoscopy and iFOBT as first-line screening 
tests. Results are expected in a decade. Recommended guidelines are based 
on statistical prediction models and case–control studies. Recent estimates 
suggest that colonoscopy has a lower effect on mortality associated with co-
lorectal cancer than previously thought, and researchers have warned that 
overly optimistic claims about its benefits have been used to sell colonoscopy 
to the general public.97 
                                                             
91 e.g. Baxter (2009), Brenner (2010) 
92 e.g. Baxter (2009) 
93 e.g. Brenner (2010) 
94 e.g. Baxter (2009) 
95 USPSTF Whitlock (2008a) 
96 USPSTF Whitlock (2008a) p. 12 
97 Betthauer (2009) p. 301 
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4.7 Characteristics of different CRC-
screening tests 
No current CRC-screening tests are without drawbacks, including potential 
harms, limited accessibility or imperfect acceptability to patients.98 The dif-
ferent CRC-screening tests are briefly described below. Details about their 
characteristics can be found in tables 4.7-1 to 4.7-7 thereafter. The different 
screening tests are numbered to facilitate finding the corresponding addi-
tional evidence in these tables. A first broad overview is given in the follow-
ing table 4.7-1. 
 
Table 4.7-1: Characteristics of commonly used CRC-screening tests 
Test CRC inci-
dence reduc-
tion* 
CRC mortality 
reduction * 
Screening in-
terval 
Invasiveness 
and prepared-
ness 
gFOBT** none 15% short (annu-
ally, bieni-
ally) 
none 
Flexible 
Sigmoid. 
*** 
18%, 21%, 
23% 
22% (not stat. 
sign.), 26%, 
31% 
long (5-10 
years, once 
only) 
invasive; less 
extensive en-
ema bowel 
cleansing 
Colon-
oscopy 
Unknown unknown long (at least 
10 years) 
invasive; more 
extensive oral 
bowel cleansing
* Figures for intention-to-screen analyses observed in randomised trials 
** low-sensitivity Hemoccult II, newer gFOBTs, i.e. Hemoccult SENSA, more sensi-
tive 
*** 2 once-only RCTs, 1 two sigmoidoscopy screening rounds RCT with 3-5 year in-
terval 
Source: updated from Bretthauer (2010) p. 1260 
 
A qualitative overview of the relative merits of the different screening tests 
was compiled by the Health Council of the Netherlands, compare table 4.11-
1. 
 
                                                             
98 USPSTF Whitlock (2008a) p.6 
no test without 
drawback: harm, 
accessibility, low 
participation 
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Tests using biomarkers 
Blood: FOBTs 
Both guaiac or gFOBT and immunochemical or iFOBT are based on the 
principle of detecting blood traces in faeces, hence the name faecal occult 
blood test FOBT. FOBTs are nonspecific tests for gastrointestinal bleeding. 
Causes relevant for CRC-screening are bleeding of CRC and of CRC-
precursor lesions. Bleeding may also result from erosion of ulcers and in-
flammatory bowel disease. In these cases FOBTs screening for CRC would 
yield false positive results in CRC-screening.99 
A wide variety of FOBTs from different manufacturers is available. Most 
countries do not require medical diagnostic tools to prove clinical efficacy 
before entering the market. This is why many FOBTs lack evidence on test 
performance, storage and transport durability.100 
1. gFOBT 
This test method has been used for around 40 years. Most chemical FOBTs 
make use of guaiac gum, which is extracted from the hardwood tree guaia-
cum officinale (gFOBT). Guaiac oxidizes when in contact with hydrogen 
peroxide, resulting in an unstable color change which has to be visually as-
sessed by a person. This reaction is catalyzed by haem, a component of hae-
moglobin common to all species. The test is not specific for human blood 
and can generate false positive and false negative results due to peroxidase 
reactions (and their inhibitors) in food products, such as red meat. gFOBTs 
lower sensitivity means that two samples must be collected from each of 
three consecutive stools, six samples in total. This renders gFOB-testing la-
borious for the screening-participant and not particularly user-friendly.101 
The result is a relatively lower participation rate in gFOBT-screening than 
in iFOBT-screening. 
The first efficacy trials (RCTs) conducted in the realm of CRC-screening 
were based on the guaiac (gFOBT) Haemoccult II test. Four RCTs with a to-
tal of 320,000 participants were conducted between 1995 and 2002 with fol-
low-up of 8-18 years, showing a relative risk reduction in CRC-specific mor-
tality of 15 % while no impact on all-cause mortality was found.102 This 
makes gFOBT the CRC-screening method with the largest RCT base dem-
onstrating effectiveness. Newer, more sensitive gFOBTs have been devel-
oped. For more information on gFOBT as a first line CRC-screening test 
compare table 4.7-1 below. 
 
 
 
 
 
                                                             
99 Bretthauer (2011) 
100 Bretthauer (2011) 
101 Health Council of the Netherlands (2009) p. 43 
102 RCTs in Gothenberg, SWE; Funen, DK; Nottingham, UK; Minnesota, US; Coch-
rane Systematic Review, Hewitson (2007) 
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2. iFOBT 
More recently a test method has been developed, which involves the immu-
nological analysis of faecal samples for occult blood (iFOBT). These tests are 
specific for human blood. The subject only has to provide a single faecal 
sample, positively affecting participation rate. Analysis of quantitative 
iFOB-testing can be automated, thus increasing quality control and reduc-
ing cost. There is micro flora in stool that can degrade the biomarker or 
hamper analysis. This problem becomes more pronounced the longer it 
takes for the stool sample to be analyzed and the higher the temperature the 
sample is exposed to during that time. Special precautions need to be taken 
to optimize the test-process in practice from stool-sampling at home to anal-
ysis in a laboratory. 
The participation rate in iFOBT CRC-screening can be expected to be high-
er than in gFOBT CRC-screening.103 In terms of sensitivity, the benefit of 
iFOBT relative to gFOBT lies primarily in the detection of early CRCs and 
advanced adenomas, which involve less bleeding than later stage CRC. This 
means that iFOBT-screening can be expected to have a greater effect on can-
cer incidence and mortality than gFOBT-screening. At equal specificity, 
iFOBT is more sensitive than gFOBT.104 For more information on iFOBT as 
a first line CRC-screening test compare table 4.7-2 below. 
3. Test using other biomarkers than blood 
The basis of CRC is a disturbance of the biological processes in the intesti-
nal epithelial cells, particularly resulting from (generally non-hereditary) 
changes in the way that certain oncogenes and tumor suppressor genes func-
tion. This disturbance is accompanied by changes in the molecular structure 
or quantity of substances such as DNA, RNA and protein. By means of labo-
ratory tests, it is possible to measure molecules of these substances – referred 
to in this context as ‘biomarkers’ – in samples of stool (see 3.1) or blood (see 
3.2). Research in this field is aimed at the identification and large-scale vali-
dation of biomarkers with better test characteristics, and optimization of the 
relevant test methodologies.105 For more information on test using other 
biomarkers than blood compare table 4.7-3 below. 
3.1 Other biomarkers in stool 
3.1.1 DNA markers in stool 
When faeces pass a tumor during progression through the bowel, tu-
mor cells or cell remnants are entrained. The excreted faeces there-
fore contain tumor DNA, which can be detected by testing.106 
 
                                                             
103 e.g. a recent study from the New Mexico Veterans Affairs Health Care System: 
61.4% vs. 50.5%; Hoffman (2010) 
104 Health Council of the Netherlands (2009) p. 47 
105 Health Council of the Netherlands (2009) p. 73 
New candidates for CRC-screening tests are of particular interest to the Swiss Cancer 
League (Krebsliga Schweiz). This is the reason for the relatively large amount of 
space allocated to the molecular markers in spite of their at this stage not being 
recommended for population based CRC-screening. 
106 Health Council of the Netherlands (2009) p. 74 
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DNA markers in stool 
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Technical challenges of the fecal DNA tests are being addressed in 
ongoing research and development. Refinements in recent laboratory 
methodologies, additional improvements of panel biomarkers that 
maximize sensitivity and specificity for both advanced adenomas and 
cancer, and cost modifications are emerging. If DNA fecal testing can 
improve compliance and reduce unnecessary diagnostic follow-up 
compared with FOBT’s, cost savings may be realized. In addition, the 
demonstration of mortality benefit in clinical trials, evidence to as-
sess the sensitivity and specificity of fecal DNA tests, and verification 
of optimal screening intervals are necessary before fecal DNA testing 
can be used as a CRC detection tool in average risk screening popula-
tions.107 
 
3.1.2 RNA markers in stool 
Faecal RNA has also been investigated as a possible CRC-
biomarker.108 
 
3.1.3 other protein markers in stool 
iFOBT is in fact a test for the presence of a protein (globin) in stool. 
Using the same principle, it should be possible to test for tumor-
specific proteins.109 One example is the enzyme M2-PK, compare ta-
ble 4.7-3.1.3. 
 
3.2 Biomarkers in blood 
For many people giving a blood sample is less inconvenient than providing a 
faecal sample. Another advantage is that in blood there is no micro flora 
which could degrade the biomarker or hamper analysis like in stool. Also 
sample processing may be easier.110 
3.2.1 DNA markers in blood 
DNA is not broken down as quickly in blood as in faeces, and blood 
contains less PCR111 inhibitory factors.112 One example is circulating 
methylated113 mSEPT9 DNA in plasma, compare table 4.7-3.2.1 
 
                                                             
107 Morrison (CADTH) (2010) p. 3 
108 Health Council of the Netherlands (2009) p. 74 
109  Health Council of the Netherlands (2009) p. 75 
110 Hundt (2007) 
111 compare: www.wikipedia.org 
Polymerase chain reaction (PCR) is a technique to amplify a single or few copies of a 
piece of DNA across several orders of magnitude, generating thoUSnds to millions 
of copies of a particular DNA sequence.  PCR is now a common and often indis-
pensable technique used in medical and biological research labs for a variety of ap-
plications. These include the diagnosis of hereditary diseases and the detection and 
diagnosis of infectious diseases. 
112 Health Council of the Netherlands (2009) p. 75 
113 compare: www.wikipedia.org 
DNA-methylation, a modification of DNA (as opposed to a genetic mutation) con-
tributes to epigenetic inheritance. 
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3.2.2 RNA markers in blood 
3.2.3 Protein markers in blood 
A systematic review of blood markers for early detection of CRC 
found the evidence thus far restricted to single studies with limited 
sample size and without further external validation.114 The authors 
conclude that larger prospective studies using study populations rep-
resenting a screening-population were needed to verify promising re-
sults. In addition, future studies should pay increased attention to the 
potential of detecting not only CRC but precursor lesions, due to 
their value for CRC-screening.115 
One of the pilot projects set up in preparation for the decision 
whether – and if, how – to initiate a population-based screening-
program in the Netherlands aims to develop molecular screening-
tests and molecular diagnostics for customized therapy. The main 
thrust of the approach is to translate recent discoveries about the mo-
lecular biology of CRC into new laboratory tests and new applica-
tions for diagnostic imaging. Existing biomarker tests are validated in 
a screening-population.116 Similar initiatives also involving acade-
mia-industry cooperation are under way in other countries.117 
Summing up, it is reasonable to believe that in more distant future a 
screening-program could be enhanced by the use of molecular mark-
ers.118 It is expected to be another few years before suitable ones can 
be identified.119 Then it will be necessary to conduct research in un-
selected populations to establish whether biomarker-based screening-
offers any advantages over the existing methods. This will take at 
least another few years. It would not be appropriate to introduce a 
new screening-test until its superiority to the existing test will have 
been demonstrated in randomized trials. Such studies can be under-
taken efficiently in the context of ongoing screening-activities.120 
Furthermore, modelling taking participation rates into account 
would need to show that the new test was more efficient than existing 
screening. 
Methods visualizing the colon 
Endoscopic methods 
4. Colonoscopy as first-line screening-test 
For characteristics of colonoscopy as a CRC-screening test compare 4.6 
above. For more information on colonoscopy as a first-line screening-test 
compare table 4.7-4 below. 
                                                             
114 Hundt (2007) 
115 Hundt (2007) 
116 Health Council of the Netherlands (2009) p. 25 
117 e.g. Germany, compare http://www.innovations-
re-
port.de/html/berichte/biowissenschaften_chemie/darmkrebs_erkennen_bevor_ent
steht_133139.html 
accessed March 14th 2010 
118 Health Council of the Netherlands (2009) p. 76 
119 Health Council of the Netherlands (2009) p. 81 
120 Health Council of the Netherlands (2009) p. 76 
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5. Flexible sigmoidoscopy 
Flexible sigmoidoscopy is a visual examination using an endoscope inserted 
through the anus into the distal (left-side) portion of the large intestine. The 
use of flexible sigmoidoscopy in CRC-screening is based on the observation 
that a majority of adenomas and cancers are located in the distal colon, with-
in reach of flexible sigmoidoscopy.121 There are fewer complications than 
with colonoscopy. Flexible sigmoidoscopy needs only limited bowel prepara-
tion – an enema prior to the examination – compared to colonoscopy or cap-
sule endoscopy. Flexible sigmoidoscopy is usually performed without seda-
tion.122 Biopsies may be taken during the procedure. A removal of polyps is 
possible.123 Inter-examiner differences in the detection of polyps have been 
shown in population-based studies of screening-flexible sigmoidoscopy.124 
These can be considerable.125 Before an effect of flexible sigmoidoscopy 
screening can be expected in screening trials, a follow-up period of at least 
10 years is required.126 
Recently the results of two large multi center randomised controlled trial of 
once only flexible sigmoidoscopy screening following a very similar protocol 
(UK, Italy)127 and one on screening with two rounds of flexible sigmoido-
scopy (US)128 were published.129 With a non-population based attendance 
rate130 of 71% the UK-trial finds a decline in disease specific mortality of 
31% (11.2 years of follow-up) and a reduction in CRC- incidence of 23% 
(11.2 years of follow-up). With a non-population based attendance rate131 of 
58.3% the Italian trial finds a decline in disease specific mortality of 22% 
(11.4 years of follow up, statistically not significant) and a reduction in 
CRC-incidence of 18% (10.5 years of follow-up).132 The lower referral 
threshold to total colonoscopy than in the UK trial adopted in the Italian 
trial133 (resulting in higher rates of colonoscopy) was not efficient in identi-
fying subjects at high risk for proximal neoplasia.134 With a non-population 
based attendance rate of 83.5% for the initial flexible sigmoidoscopy and 
54.0% for the second round of flexible sigmodoscopy screening either 3 or 5 
                                                             
121 Bretthauer (2011) 
122 Bretthauer (2011) 
123 e.g. Atkin (2010) 
124 e.g. Barclay (2006) 
125 Bretthauer (2011) 
126 Bretthauer (2011) 
127UK-NHS-Trial Atkin (2010), ITA-SCORE-Trial Segnan (2011) 
128 US-PLCO-Trial Schoen (2012) 
129 Results reported her based on intention-to-screen analysis. 
130 Subjects were recruited only after affirmatively answering a questionnaire about 
their willingness to participate in CRC-screening if offered. 
131 Subjects were recruited only after affirmatively answering a questionnaire about 
their willingness to participate in CRC-screening if offered. 
132 UK and Italian trials both not population based, since subjects were recruited on-
ly after affirmatively answering a questionnaire about their willingness to partici-
pate in CRC-screening if offered. Protocol followed almost identical, flexible sig-
moidsocopies performed in hospital settings, Italian trial had lower threshold for 
referral to colonoscopy. 
133 Referral threshold to total colonoscopy in UK trial: large distal polyps >= 10mm, 
smaller advanced adenomas < 10mm; referral threshold in Italian trial: small ad-
vanced adenoma <= 5mm and any distal polyp > 5mm; Segnan (2011) 
134 Segnan (2011) 
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years later135, the US-trial finds a decline in disease specific mortality of 
26% (11.9 years of follow-up) and a reduction in CRC-incidence of 21% 
(11.9 years of follow-up). The threshold for referral to total colonoscopy in 
the US-trial was even lower than in the Italian trial, resulting in the highest 
number of colonoscopies performed.136 
Colorectal cancer screening guidelines usually recommend flexible sigmoi-
doscopy with a five year screening interval. Summing up the evidence from 
both the UK and the Italian trial Segnan et al. don’t expect a substantial in-
crease in the protective effect of screening by repeating flexible sigmoido-
scopy before 10 years. They infer that flexible sigmoidoscopy screening may 
not need to be repeated.137  
Adequately trained nurse practitioners can (and did in the UK and US-
trials) undertake flexible sigmoidoscopy as competently as can gastroen-
terologists and public acceptance of nurse led flexible sigmoidoscopy is 
high.138 
The UK, Italian and US trials provide valid and robust evidence for the effi-
cacy of flexible sigmoidoscopy screening. The effectiveness of such screening 
in the general population is still uncertain, however, because the trials did 
not recruit directly from the general population. NORCCAP139 is the only 
study of flexible sigmoidoscopy screening that is truly population based and 
will provide an estimate of effectiveness after 10 years of follow-up in 
2013.140 
For more information on flexible sigmoidoscopy as a first-line CRC-
screening test compare table 4.7-5 below. 
6. Capsule Endoscopy 
Capsule endoscopy is a technique in which the subject swallows a capsule 
that takes photographs at regular intervals while it travels through the large 
bowel.141 These images are transferred wirelessly to an external receiver, 
which is worn by the individual being examined. After 24 hours, the data ac-
cumulated by the receiver is downloaded and the images are examined on a 
monitor. At the end of the examination period the capsule is ejected from 
the body with the faeces. Extensive bowel preparation is needed. Biopsy or 
removal of polyps is not possible. The rate of detection of polyps is depend-
ent on the skills of the examiner. 
“With the capsule’s relatively low sensitivity for the detection of colorectal 
lesions, its requirement for more extensive bowel-cleansing regimens as 
compared with colonoscopy and CT colonography, and its high cost, colon 
capsule endoscopy cannot be recommended [for cancer screening] at this 
time.”142 
                                                             
135 86.6% underwent at least one flexible sigmoidoscopic screening, 50.9% underwent 
two screenings, 80.5% of participants with positive finding followed suggestion to 
undergo further diagnosis within a year (95.6% of these colonoscopy), Schoen 
(2012) 
136 5% UK-trial, 8.4% Italian trial, 21.9% US trial; Schoen (2012) 
137 Segnan (2011) 
138 Atkin (2010) 
139 Hoff (2009) 
140 Bretthauer (2010); For preliminary findings of NORCCAP-trial after only seven 
years of follow-up compare Hoff (2009). 
141 Health Council of the Netherlands (2009) p. 65 
… evidence may point 
to longer screening 
intervals for FS or even 
once-only FS 
…trained nurses as 
alternatives 
FS now has robust 
evidence base for use in 
CRC-screening 
…trained nurses as 
alternatives 
no serious complications 
polyp detection 
operator-dependent 
extensive bowel 
preparation necessary 
not recommended for 
screening at this stage 
Screening for Colorectal Cancer 
44 LBI-HTA | 2012 
For more information on capsule endoscopy as a first-line CRC-screening 
test compare table 4.7-6 below. 
Virtual endoscopic methods 
7. Colonography 
Colonography or “virtual colonoscopy” involves examination of the entire 
large intestine by means of CT-scanning143, preferably after limited bowel 
preparation (1-day low-fiber diet, oral contrast agent for the uniform stain-
ing of stool residue and moisture). To achieve colonic distension carbon di-
oxide is delivered via a rectal catheter. Examinations are performed in both 
supine and prone position. Biopsy or removal of polyps is not possible. For-
mal standards for performing CT-colonography are lacking.144 The chal-
lenges of adequately ensuring high-quality CT-colonography readings are il-
lustrated by reports that half of the radiologists did not pass the initial certi-
fying examination after 1.5 days of training or experience with more than 
500 cases.145 Complications tend not to be serious. In the case of CT-
colonography exposure to ionized radiation is a largely unexplored problem 
Extra-colonic findings during CT-colonography are also an issue. Evaluation 
of images generated during CT-colonography also involves findings of struc-
tures outside the colon itself. In the case of serious, treatable disorders this 
might be an advantage. Among the target group for population-screening, 
the chance that a serious, treatable disease will be found is quite small, 
though. Extra-colonic findings can also be a disadvantage: Screening may 
reveal disorders such as an aneurysm of the aorta, for which the usefulness 
of early detection is not a foregone conclusion. What is clear, however, is 
that the reporting of extra-colonic abnormalities can double the number of 
referrals for diagnosis.146 The use of low radiation dosage reduces image 
quality outside the colon and is expected to significantly reduce the number 
of referrals due to extra-colonic findings after screening with CT-
colonography.147  
Given potential harms and observed variability in test accuracy, emphasis on 
quality standards für implementation of any operator-dependent CRC-
screening test appears prudent.148 
A RCT from the Netherlands found that people invited to screening via CT-
colonography perceived the procedure (ahead of it) as less burdensome than 
colonoscopy. After actually having undergone the procedure, CT-
colonography screenees perceived it as having been more burdensome than 
colonoscopy screenees. Intended participation in a future round of screening 
was comparable.149 
                                                                                                                                   
142 Betthauer (2009) p. 300 
143 also MRI-scanning is possible 
144 Pox (2010) 
145 USPSTF Whitlock (2008) 
146Health Council of the Netherlands (2009), p. 68 
147 Health Council of the Netherlands (2009), p. 68 
148 USPSTF Whitlock (2008) 
149 de Wijkerslooth (2011) 
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Another RCT from the Netherlands found attendance rates for CT-
colonography screening to be higher than those for colonoscopy screening 
(34% vs. 22%).150 
Large prospective multi-center trials are warranted to collect data on CT-
colonography as a candidate for first-line screening test in the average risk 
population.151 For more information on CT-colonography as a first-line 
CRC-screening test compare table 4.7-7 below. 
                                                             
150 Stoop (2012) 
151 Kaufman (2010) 
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Table 4.7-1: Detailed characteristics of gFOBT as CRC-screening test 
Test Evidence 
on 
effectiveness 
 
Expected partici-
pation rate 
Number of re-
sulting colono-
scopies 
Sensitivity of test Specificity of test Information 
1. 
gFOBT 
4 RCTs with traditional 
lower-sensitivity gFOBT 
 
1975-2002 
 
follow-up: 
8-18 years 
 
320,000 participants 
 
disease-specific CRC-
mortality: 
RRR 11-18% 
 
no impact on all-cause 
mortality found 
lower than iFOBT 
 
around 50% 
 
47-50% 
in NL trials 
n.a. 
 
lower-sensitivity 
gFOBT has 
smallest number 
of resulting C of 
all screening 
strategies 
limited 
 
HCII test-
sensitivity: 
CRC 
13-38% 
 
HCII biennial pro-
gram sensitivity: 
CRC 
50-60% 
 
(today higher-
sensitivity gFOBTs 
available, e.g. He-
moccult SENSA) 
CRC 
99% 
 
PPV for advanced 
neoplasia: 
50% 
 laborious and user unfriendly: two samples each on three consecutive 
stools necessary, six altogether 
 negative impact on participation 
 test is not specific for human blood and can generate false positive and 
false negative results due to peroxidase reactions (and their inhibitors) 
in food products, such as red meat 
 dietary measures necessary before test 
 medication use can influence test (vitamin c, aspirin etc.) 
 color change unstable, has to be visually assessed 
 reader dependence 
COMPLICATIONS 
 gFOBT: no studies exist152, assumption: none 
 follow up-colonoscopy, see Table 4.7-4 
Abbreviations: C … colonoscopy 
CE … capsule endoscopy 
 
HCII … Hemoccult II: low sensitivity gFOBT  
 
 CI … confidence interval iFOBT … immunochemical FOBT NordICC … The Nordic-European Initiative on Colorectal 
 CRC … colorectal cancer ITA … Italy Cancer 
 CT-C … computed tomography-colonography mm … millimeters 
n.a. … not available 
PPV … positive predictive value, percentage of true positives among test posi-
tives 
 DNA … deoxyribonucleic acid NL … Netherlands RCT … randomized controlled trial 
 FOBT … faecal occult blood test 
FS … flexible sigmoidoscopy 
NL-CoCoS … Population screening for colorectal 
cancer by colonoscopy or CT-
colonography in the Netherlands 
RNA … ribonucleic acid 
RRR … relative risk reduction 
 gFOBT … guaiac faecal occult blood test NNScope … number needed to scope UK … United Kingdom 
Source:  information from Health Council of the Netherlands (2009), adapted with specifically cited inputs 
                                                             
152 USPSTF Whitlock (2008) 
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Table 4.7-2: Detailed characteristics of iFOBT as CRC-screening test 
Test Evidence 
on 
effectiveness 
Expected partici-
pation rate 
Number of result-
ing colono-scopies
Sensitivity of test Specificity of test Information 
2. 
iFOBT 
little data available on 
regularly repeated 
iFOBT-screening 
 
1 study found CRC-
mortality: 
RRR 32% 
(because of cluster ran-
domization methodically 
problematic) 
 
numerous observational 
studies 
60-62% 
in NL trials 
35/1,000 
 
assuming partici-
pation rate of 
60% and referral 
threshold of 
75ng/ml 
higher than gFOBT 
 
estimates show var-
iability within each 
test, possibly be-
cause of different 
collection methods, 
reference stan-
dards153 
 
depending on spe-
cific test and referral 
threshold (of quan-
titative iFOBTs) set 
in program 
 
test-sensitivity: 
CRC 
55-90% 
lower than gFOBT
 
depending on spe-
cific test and re-
ferral threshold 
(of quantitative 
iFOBT) set in pro-
gram 
 
PPV for advanced 
neoplasia: 
33% 
 more false positives than gFOBT 
 for screening-participants more user friendly sampling, more reliable, 
more hygienic than gFOBT 
 positive impact on participation 
 iFOBT detects more early CRCs and advanced adenomas, which involve 
less bleeding than later stage CRC, than gFOBT 
 iFOBT-screening can be expected to have a greater effect on cancer 
incidence and mortality 
 at equal specificity, iFOBT is more sensitive than gFOBT 
 some iFOBTs are quantitative in nature 
 adjusting threshold enables screening to be more focused and 
cost-effective 
  automated testing (reader independent, cheaper) 
 little data available concerning an optimum referral threshold to C154  
test characteristics of screening dependent on it: the lower the threshold 
 the higher the sensitivity 
 the higher the number of participants who have to be referred to 
C 
 the higher the number of false positives (i.e. the lower the speci-
ficity) 
 no convincing evidence to suggest that iFOBT-screening is less effective 
in detecting proximal tumors as opposed to distal tumors (like FS for 
obvious reasons but also C) 
 no clear evidence of adverse risk selection (in which fewer individuals 
from high-risk groups participate) as is the case with cervical-cancer 
screening 
 iFOBT yields better participation rates, detection rates and is signifi-
cantly more cost effective than gFOBT-screening (NL trials) 
COMPLICATIONS 
 iFOBT: no studies exist155, assumption: none 
 follow up-colonoscopy, see Table 4.7-4 
Abbreviations: see table 4.7-1 above  
 
Source:  information from Health Council of the Netherlands (2009), adapted with specifically cited inputs 
 
                                                             
153 USPSTF Whitlock (2008) 
154 for study on referral threshold from the Netherlands compare Wilschut (2011) 
155 USPSTF Whitlock (2008) 
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Table 4.7-3: Detailed characteristics of bio-markers other than blood as CRC-screening test 
Test Evidence 
on 
effectiveness 
Expected par-
ticipation rate
Number of  
resulting  
colono-scopies 
Sensitivity of test Specificity of test Information 
3. 
Bio-markers other 
than blood 
 
numerous candidate biomarkers 
 
development of practical tests 
ongoing 
 
large-scale validation studies for 
use in CRC-screening required 
thereafter 
    biomarkers: DNA, RNA, proteins in faeces or blood 
 clinical accuracy data on faecal DNA tests is still too limited to support 
population-screening156 
 biomarkers do not yet constitute a realistic alternative to FOBT 
 mismatch between small number of available clinical studies on faecal 
DNA tests and larger number of commercially available tests157 
 progress is being made with development of numerous candidate bio-
markers158 
 development of practical tests will require the involvement of companies 
capable of marketing the tests 
 development work by companies focuses exclusively on markers over 
which intellectual property rights have been secured 
3.1.3 
 
faecal M2-PK  
(enzyme) 
evidence on detecting precur-
sors to CRC scant and contro-
versial159 
 
one larger study among 1,082 
screening-participants in Ger-
many: Haug (2008) 
 
one study prospectively com-
paring office-based iFOBT and 
M2-PK in 600 subjects above 
average risk: Shastri (2008) 
  cut-off 4U/ml 
 
Haug (2008) 
advanced adeno-
mas: 
22% 
other adenomas: 
23% 
 
Shastri (2008) 
CRC and large ad-
enomas >10mm: 
72,4% 
cut-off 4U/ ml 
 
Haug (2008) 
82% 
 
Shastri (2008) 
CRC and large ad-
enomas >10mm: 
73,8% 
 tumor M2-PK is an isoform of the glycolytic enzyme PK, which is over ex-
pressed in proliferating cells such as tumor cells 
 test has been proposed for early detection of CRC 
 test has only very limited potential to distinguish between people bearing 
precursors to CRC and people with no finding at C160 
 poor performance characteristics demonstrated do not certify further use 
as a screening-tool in CRC and large adenomas161 
                                                             
156 USPSTF Whitlock (2008a) 
157 USPSTF Whitlock (2008a) 
158 e.g. Morrison (CADTH) (2010) 
159 Haug (2008) 
160 Haug (2008) 
161 Shastri (2008) p. 1502 
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Test Evidence 
on 
effectiveness 
Expected par-
ticipation rate
Number of  
resulting  
colono-scopies 
Sensitivity of test Specificity of test Information 
3.2.1 
 
methylated SEPT9 
DNA in blood plas-
ma 
deVos (2009) 
single, small producer affiliated 
study on test for detection of 
invasive colorectal adenocarci-
noma only (not for detection of 
precursor lesions) 
     study undertaken in non-screening population 
 study with screening-population underway 
 development of test for precursor lesions, that would shed light on possi-
ble future benefit as CRC-screening test, is under way162 
 
Abbreviations: see table 4.7-1 above   
Source:  design of table from Health Council of the Netherlands (2009), input from 2009 hand search for studies on molecular tests 
 
 
Table 4.7-4: Detailed characteristics of colonoscopy as CRC-screening test 
Test Evidence on 
effectiveness 
Expected  
participation rate 
Number of  
resulting  
colonoscopies 
Sensitivity of test Specificity of test Information 
4. 
Colonoscopy 
C 
limited data available on 
the effect of C-screening 
on CRC-incidence and 
mortality 
 
no evidence yet avail-
able from RCTs: results 
from two163 RCTsl ex-
pected in about 10+ 
years 
 
NNScope* either CRC or 
advanced adenomas: 
13 
 
NNScope* CRC: 125 
unknown 
 
initial data 
20-40% 
 
NL-CoCoS-trial an-
ticipates 20-25% 
250/1,000 
(assuming par-
ticipation rate of 
25%) 
C is (imperfect) 
reference standard
 
insufficient evi-
dence to provide 
precise estimates 
in community set-
tings164 
 
CRC: 
>97% 
 
adenomas 
>10mm: 
90-98% 
 
  small risk of serious complications including death 
 serious harms from community C are about 10 times more common than 
with FS166 
 screening-yield is heavily dependent on the endoscopist 
 participation in C-screening significantly lower than in iFOBT-screening 
 program detection rate lower with difference increasing in subse-
quent screening-rounds 
 unpleasant screening-method due to its invasive nature 
 extensive bowel preparation necessary at home on preceding day: drinking 
of 2 liters of laxative solution 
 participants in screening have to reserve 2 days for entire procedure (bow-
el preparation, aftercare) 
 C itself takes approx. 20 minutes 
 most sensitive existing test for detecting advanced neoplasia (imperfect 
reference standard) 
 C misses some polyps and may also miss CRC167 
                                                             
162 compare http://www.innovations-report.de/html/berichte/biowissenschaften_chemie/darmkrebs_erkennen_bevor_entsteht_133139.html 
accessed March 14th 2010 
163 Barcelona, Spain: Colorectal Cancer Screening in Average-Risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy 
Trial registered at www.ClinicalTrials.gov with registration no: NCT00906997 
once only colonoscopy, NordICC is a multicentre, randomised trial in Nordic countries, the Netherlands and Poland 
Trial is registered at www.ClinicalTrials.gov with registration no: NCT0088379 
164 USPSTF Whitlock (2008) 
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Test Evidence on 
effectiveness 
Expected  
participation rate 
Number of  
resulting  
colonoscopies 
Sensitivity of test Specificity of test Information 
adenomas 
6-9mm: 
87% 
 
miss rates for ade-
nomas >10mm 
possibly higher 
than CT-C165 
 tumors in the right (proximal) colon are harder to detect for C those in the 
left (distal) colon 
o different nature of right (proximal) and left sided (distal) tu-
mors; sessile (flat) abnormalities, that are more difficult to de-
tect, are more frequent in the proximal colon – as opposed to 
much more common and easier to detect pedunculated (spheri-
cal) polyps 
o anatomic “blind spots” 
o incomplete bowel preparation 
o incomplete C 
 if needed, polypectomy or biopsy possible during same screening-
procedure 
 evidence for timing of C-screening is limited, suggesting re-screening 
would be needed once every 10 years, or up to 20 years and more168, pos-
sibly once-only triage screening also an option to consider169 
 considerable C-capacity required 
COMPLICATIONS of screening-colonoscopy with evolving evidence base 
 procedure related hospital visits 950/ 100,000170 
 serious complications from C in asymptomatic populations 310/ 100,000171 
o perforation: 56/ 100,000172 and 66/ 100,000173 and 50 - 10/ 
100,000174 
o bleeding: 120/ 100,000175 and 60 - 20/100,000176 
 
 
                                                                                                                                                                                                                                                                                                                 
165 USPSTF Whitlock (2008a) 
166 USPSTF Whitlock (2008) 
167 USPSTF Whitlock (2008) 
168 e.g. Brenner (2008), Brenner (2010) 
169 Bretthauer (2012) 
170 Leffler (2010) 
171 USPSTF Whitlock (2008a) – Serious complications were defined as adverse events requiring hospital admission, including perforation, major bleeding, diverticulitis, severe abdominal pain, cardio-
vascular events, and deaths attributable to colonoscopy (p. 24). 
172 USPSTF Whitlock (2008a) 
173 Van Heijningen (2010) 
174 Health Council of the Netherlands (2009) 
175 USPSTF Whitlock (2008a) 
176 Health Council of the Netherlands (2009) 
177 Van Heijningen (2010) 
178 e.g. Heher (2008) 
179 Lieberman (2009) 
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Test Evidence on 
effectiveness 
Expected  
participation rate 
Number of  
resulting  
colonoscopies 
Sensitivity of test Specificity of test Information 
 death: most screening-studies indicate no fatal outcomes of screening-C 
o death from colonoscopy for symptomatic patients: 4/ 100,000 
 patients older than screening-population 
 more co-morbidities 
 more intestinal problems 
o overall death from colonoscopy: 6/ 100,000177 
 from bowel preparation178 
 from sedation, not systematically documented and linked to interven-
tion179 
COMPLICATIONS of follow-up C after positive first-line screening-test are 
higher than for screening-C 
 perforation: 100/ 100,000 
 bleeding: 140/100,000 
* ... On the basis of prevalence figures from the Netherlands: for every 13 people who undergo colonoscopy in the context of screening, just one will be found to have either CRC or advanced adenomas. 
For every 125 people who undergo colonoscopy in the context of screening just one will be found to have CRC – see Health Council of the Netherlands (2009) 
Abbreviations: see table 4.7-1 above   
Source:  information from Health Council of the Netherlands (2009), adapted with specifically cited inputs 
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Table 4.7-5: Detailed characteristics of flexible sigmoidoscopy as CRC-screening test 
Test Evidence on 
effectiveness 
Expected par-
ticipation rate
Number of result-
ing colono-scopies
Sensitivity of 
test 
Specificity 
of test 
Information 
5. 
Flexible sig-
moidoscopy 
FS 
results from three large non-
population based RCTs180, intention to 
treat analysis181: 
Atkin (2010) 
CRC mortality minus 31% 
CRC incidence minus 23% 
Segnan (2011) 
CRC mortality minus 22% 
(statistically NOT signifi-
cant) 
CRC incidence minus 18% 
Schoen (2012) 
CRC mortality minus 26% 
CRC incidence minus 21% 
 
 
results from population based trial ex-
pected in 2013182 
 
 
from NL trial: 
 
NNScope* CRC 
 625 invitations 
 207 FS 
 18 C 
 
NNScope* advanced adenomas 
 48 invitations 
 16 FS 
 1-2 C 
10-40% 
 
Atkin (2010) 
71%183 
Segnan (2011) 
58.3%184 
Schoen (2012) 
86,6%185 
 
more realistic:
32% 
in Rotterdam 
trial 
Atkin (2010)186 
50/1000 
more realistic: 
18/1,000 
on top of 350 FS 
assuming 35% par-
ticipation rate un-
der population 
based screening 
conditions 
 
Segnan (2011)187 
84/1000 
Schoen (2012)188 
219/1000 
 
 
27/1,000 
 
on top of 327 FSs  
 
assuming partici-
pation rate of 32%
little data avail-
able concerning 
sensitivity in 
population-
screening 
 
based on C-
studies in aver-
age risk popula-
tion (over-
estimation): 
 
CRC: 
58-75% 
 
advanced neo-
plasia: 
72-86% 
 
  serious harms from community FS are about 10 times less common than with 
C189 
 estimates for harms from FS have much wider confidence intervals190 
 screening-yield is heavily dependent on the endoscopist 
 adequately trained nurse practitioners can undertake FS as competently as can 
gastroenterologists and public acceptance of nurse led flexible sigmoidoscopy is 
high191 
 FS takes only about 5-7 minutes, less than colonoscopy (20 mins.) 
 uptake significantly lower than for iFOBT-screening (NL trial) 
 uptake would need to be significantly higher than projected 30% (NL trial) to 
render FS an effective screening-method 
 roughly equally sensitive for CRC as single iFOBT 
 significantly more sensitive for advanced adenomas 
 not clear whether screening needs to be repeated every 5 or 10 years 
 limited bowel preparation – less extensive than for C 
o enema 120-150ml, possibly self-administered 
o 9-20% of participants have to make new appointment due to in-
adequate preparation 
 no data available concerning an optimum referral threshold to C  test charac-
teristics of screening dependent on it: the lower the threshold 
 the higher the sensitivity 
 the higher the number of participants who have to be referred 
 the higher the number of false positives (i.e. the lower the specificity) 
COMPLICATIONS 
 FS serious complications: 34/100,000 (CI 6-190)192 
o FS perforation: 4.6/ 100,000193 and 2-3/100,000194 
 FS from limited bowel preparation 
 follow up-colonoscopy, see table 4.7-5 
                                                             
180 2 RCTs once-only sigmodoscopy; 1 two rounds of sigmoidoscopy screening, 3-5 years apart 
181 Intention-to-treat analysis: all participants allotted to the screening group, including those who decided not undergo screening as opposed to per-protocol analysis, only participants actually 
screened 
182 once only sigmoidoscopy, NORCCAP trial, preliminary results after only 7 years of follow up: Hoff (2009) – NORCCAP is the only study of flexible sigmoidoscopy screening that is truly population 
based and will provide an estimate for effectiveness after 10 years of follow-up in 2013. 
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* ... On the basis of prevalence figures from the Netherlands: for  one person to be found to have CRC or advanced adenomas 16 will need to undergo flexible sigmoidoscopy and 1-2 follow-up colono-
scopy, In the case of CRC  alone, the figures are 207 and 18 – Health Council of the Netherlands (2009) 
Abbreviations: see table 4.7-1 above   
Source:  information from Health Council of the Netherlands (2009), adapted with specifically cited inputs 
                                                                                                                                                                                                                                                                                                                 
183 This figure is an estimate of the participation in a population based screening based on Atkin (2010). This UK RCT was designed to have high power to examine the efficacy of FS (incidence and 
mortality of CRC). It was not designed to determine realistic participation rates in FS based population based screening. The RCT therefore had a pre-selected population. Participants in RCT were 
only enrolled after answering “Yes” to the question if they would participate in FS screening if invited. This meant that the compliance rate in the trial was (much) higher than would be expected in 
population based screening. Of the invited 71% participated in FS screening. But 47% of the potential screening population were excluded from being invited. Assuming that the excluded would not 
have participated in the screening the participation rate in a population based screening might be estimated to be a little above 35%. 
184same problem as Atkin (2010) 
185 not population-based, unrealistic 
186 Referral threshold to total colonoscopy: large distal polyps >= 10mm, smaller advanced adenomas < 10mm; Segnan (2011) 
187 unrealistic participations rate, lower threshold for colonoscopy than Atkin (2010): small advanced adenoma <= 5mm and any distal polyp > 5mm; Segnan (2011) 
188 unrealistic participations rate, lower threshold for colonoscopy still than Segnan (2011):detection of any polyp or mass ; Schoen (2012) 
189 USPSTF Whitlock (2008) 
190 USPSTF Whitlock (2008) 
191 Atkin (2010) 
192 USPSTF Whitlock (2008a) – Serious complications were defined – in analogy to colonoscopy – as adverse events requiring hospital admission, including perforation, major bleeding, diverticulitis, 
severe abdominal complaints, myocardial infarction, syncope, and deaths attributable to flexible sigmoidoscopy (p. 26). 
193 USPSTF Whitlock (2008a) 
194 Health Council of the Netherlands (2009) 
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Table 4.7-6: Detailed characteristics of capsule endoscopy as CRC-screening test and new developments in endoscopy 
Test Evidence on 
effectiveness 
Expected  
participation rate 
Number of  
resulting  
colonoscopies 
Sensitivity of test Specificity of test Information 
6. 
Capsule endoscopy 
CE 
small, producer spon-
sored studies only 
no data available  Spada (2010) 195 
CRC: 76% 
adenomas 
>6mm: 68% 
 
Van Gossum 
(2009) 196 
CRC: 74% 
adenomas 
>6mm: 64% 
adenomas 
>10mm: 
64 % 
Adenomas >6mm 
82%197 
 CE has been widely used to analyze pathologies of the small intestine for 
several years198 
 current price of a capsule approx. € 950.-199 
 need for extensive bowel preparation, more extensive than for colono-
scopy or CT-colonography 
 in the coming  years, improvements may be expected to make CE suitable 
for use as a method of CRC-screening 
 randomized studies, involving comparisons with existing screening-
methods, will then have to be carried out to determine whether CE can 
actually improve the efficacy or efficiency of screening 
 battery life limits the use of this technique as a screening-method for CRC 
o remedy: use of capsules with delayed activation, reduced 
energy consumption, increased battery capacity 
COMPLICATIONS 
 CE: from bowel preparation 
 follow up-colonoscopy, see table 4.7-5 
New developments 
in endoscopy 
      more adenomas can be detected using chromoscopy (colonoscopy in which 
the intestinal wall is stained) 
 this technique is very time consuming and does not appear to be suitable 
for use as a general screening-method 
 same is true of 
o high-definition endoscopes 
o auto fluorescence narrow-band imaging 
Abbreviations: see table 4.7-1 above   
Source:  information from Health Council of the Netherlands (2009), adapted with specifically cited inputs 
                                                             
195 Meta analysis of 8 studies with data on 837 patients 
196 producer supported study on 320 patients, sensitivity probably overestimated compare Bretthauer (2009) 
197 Spada (2010) 
198 Capsule endoscopy has become part of the reimbursement basket for Germany’s social health insurance to investigate unclear bleeding in the small intestine in November 2010. See Gemeinsamer 
Bundesausschuss, www.g-ba.de 
199 Bretthauer (2009) 
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Table 4.7-7: Detailed characteristics of CT-colonography as CRC-screening test 
Test Evidence on 
effectiveness 
Expected partici-
pation rate 
Number of  
resulting  
colono-scopies 
Sensitivity of test Specificity of test Information 
7. 
Computed-
Tomography colon-
ography 
CT-C 
no evidence from ran-
domized trials that CT-C 
reduces CRC-incidence 
and CRC-mortality 
Unknown 20/1,000 
 
assuming a par-
ticipation rate of 
35% and a polyp 
referral thresh-
old of 10mm 
 
referral thresh-
old of 6mm ap-
prox. doubles 
number of Cs 
limited evidence 
on performance in 
population screen-
ing-programs 
 
variability be-
tween readers lim-
its ability to pro-
vide precise esti-
mates200 
 
advanced neopla-
sia: 
97% 
 
less sensitive for 
small adenomas 
 
detection of ade-
nomas >10mm 
possibly higher 
than C201 
limited evidence 
on performance in 
population screen-
ing-programs 
 
estimates are 
somewhat uncer-
tain202 
 
for large polyps: 
>95% 
 
PPV advanced ad-
enomas: 
 
41% 
(referral threshold 
6mm) 
 
52-67% 
(referral threshold 
10mm) 
 almost identical sensitivity for CRC-cancer and polyps >10mm as C 
o possibly more sensitive for larger lesions than C, less 
so for smaller lesions203 
 screening-yield is heavily dependent on radiologist 
 variety of technologies used204 
o varying slice thickness 
o single/multi detector scanner 
o 2D/ 3D/ 3D fly-through 
o oral contrast 
 radiation dosage expected to decline with future progress in CT-
technology: 
o lower radiation exposer for CRC-screenees  
o low radiation dosage reduces image quality outside the co-
lon and is expected to significantly reduce the number of re-
ferrals from extracolonic findings205 
 subjects expect CT-C to be less unpleasant than C 
 clear preference for CT-C in studies of subjects’ experience 
 clear preference for CT-C in people who have undergone both CT-C and C 
 may be superior to C for detecting proximal CRC 
 sessile (flat) abnormalities, which are more common in the proximal colon 
– as opposed to much more common pedunculated (spherical) polyps – are 
difficult to detect 
 less likely to have serious complications than C 
 limited bowel preparation – less than for C 
 no agreement on best referral threshold to C – usually ≥ 6 mm  test 
characteristics of screening dependent on it: the lower the threshold 
 the higher the sensitivity 
 the higher the number of participants who have to be referred to C 
 the higher the number of false positives (i.e. the lower the specific-
ity) 
 examination takes about 15 mins., reading about 10 mins. 
 
COMPLICATIONS 
 CT-C radiation 
 CT-C issue of extra-colonic findings unresolved 
 CT-C from limited bowel preparation 
 follow up-colonoscopy, see table 4.7-5 
                                                             
200 USPSTF Whitlock (2008) 
201 USPSTF Whitlock (2008a) 
202 USPSTF Whitlock (2008) 
203 USPSTF Whitlock (2008) 
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Abbreviations: see table 4.7-1 above   
Source:  information from Health Council of the Netherlands (2009), adapted with specifically cited inputs 
 
 
                                                                                                                                                                                                                                                                                                                 
204 USPSTF Whitlock (2008a) 
205 Health Council of the Netherlands (2009), p. 68 
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4.8 CRC-screening activities worldwide 
European Union 
Finland, England and Scotland are currently working on the phased intro-
duction of nationwide population-based screening-programs.206 Nationwide 
population-based programs are at the preparatory stage in 5 other countries, 
while France, Spain, Italy and Sweden already have population screening-
programs in place at regional level. Italy has a national body for the evalua-
tion of its 72 regional screening-programs for CRC. In total, the population-
based programs that are either in preparation or already under way cover 43 
% of the target population in the EU207. Many countries have a variety of 
obstacles to a nationwide population-based program, such as a decentralized 
health care services and public-health policy determination. For example, 
Germany, Austria and the Czech Republic have established non-population-
based programs. Screening in those countries is carried out on an individual 
basis (27% of the target group). This is referred to as opportunistic screen-
ing. The participation rates involved are low. 8 of the 27 member states have 
yet to start preparing screening-programs of their own. In 2007, 12 million 
people actually underwent screening for CRC. On the basis of a biennial 
screening, this represents 18% of the target group. Most of the countries 
with a national screening program use gFOBT.208 CRC-screening with 
iFOBT is on the rise, though. Italy selected iFOBT-screening, so did Ireland 
and the Netherlands and the UK is considering a switch to that system in 
the near future. The primary screening-test in Poland is colonoscopy. In 6 
countries, endoscopic screening is used in combination with – or as an alter-
native to – FOBT-screening. 5 of these states (including Germany, Austria) 
use colonoscopy while Italy uses flexible sigmoidoscopy. 
In Ireland a national colorectal cancer screening programme started inviting 
60-69 year old men and women for biennial iFOBT based CRC-screening in 
2012. The choice of screening test was based on cost-effectiveness analy-
sis.209 Eventually the program is set to include the age range from 55 to 74. 
Screening colonoscopies after referrals will take place at contracted units in 
hospitals.210 In advance of the decision to organise a population based 
screening program the Irish government commissioned a thorough analysis 
of screening options and important issues to be considered. These HTA doc-
uments can be downloaded on the internet.211 
 
                                                             
206 For this section compare Health Council of the Netherlands (2009) p. 21 
207 For the situation in the EU compare also e.g. Gutierrez-Ibarluzea (2008) 
208 Wilschut (2011) 
209 Sharp (2012) 
210 www.cancerscreening.ie und 
www.cancerscreening.ie/publications/ImplementingColorectalProgramme.pdf 
211 
www.hiqa.ie/news_releases/090617_HTA_colorectal_cancer_screening_programme
.asp 
Finland, England, 
Scotland phase in 
population-based 
screening 
43% of target 
population in EU have 
access to some sort of 
screening 
opportunistic screening 
with low participation 
rate 
gFOBT most common 
test 
Ireland begins 
population based 
biennial iFOBT 
screening program 
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Outside the EU 
Countries like Australia and 3 of the 10 Canadian provinces have com-
menced the phased introduction of population-screening based on gFOBT, 
iFOBT or flexible sigmoidoscopy. In the US, Japan and Taiwan, screening 
takes place on an individual basis. Colonoscopy is the most widely used 
technique in the US. In 2002, 14 million colonoscopies were carried out in 
the US, approximately 40% of which involved primary screening. Colono-
scopy utilization for screening has increased recently, and use of flexible sig-
moidoscopy decreased, due largely to the decision in 2001 to cover screen-
ing-colonoscopy for patients on Medicare, and similar decisions by private 
pay insurers.212 Over 20% of colonoscopies in the US were performed as part 
of the surveillance of high-risk groups. Japanese citizens who are over 40 
years of age and who have health insurance cover have been offered iFOBT-
screening since 1992. Only 17% of the target group made use of this facility 
in 2002. There is no provision for the evaluation of the screening-program. 
The sum total of current programs throughout the world represents a con-
siderable amount of screening-activity. Many such programs have been un-
der way for many years, as in Japan, Italy and Germany. Nevertheless, only a 
few countries like the UK and soon Ireland and the Netherlands have organ-
ized, nationwide, population-based screening-programs. 
4.9 Current CRC-screening recommendations 
by selected institutions 
EU guidelines for colorectal cancer screening 
 
Comprehensive guidelines for quality assurance of colorectal cancer screen-
ing which are suitable for implementation throughout the 27 EU Member 
States were developed in a project coordinated by International Agency for 
Research on Cancer IARC and co-funded by the EU Health Programme. 
The most fundamental principle being that screening should be imple-
mented in the context of an organized, population-based programme follow-
ing comprehensive quality assurance guidelines. Adequate attention needs 
to be paid to planning and training, identification and information of the 
target population, multidisciplinary management of detected lesions, as well 
as to coordination, monitoring and evaluation.213 
 
When analyzing CRC-screening recommendations, the different respective 
health system background, stakeholder pressures and target audience for the 
screening-recommendations should be born in mind. Recommendations 
from different organizations also vary because the rationale behind the rec-
ommendations differs (prevention of cancer, early detection of cancer, un-
equivocal advice to clinicians, …)214. The Health Council of the Netherlands 
for instance, got the specific task from the minister of health to formulate 
recommendations for a national screening-program that should take the re-
                                                             
212 USPSTF Whitlock (2008a) p. 7 
213 For the “European guidelines for quality assurance in colorectal cancer screening 
and diagnosis.-First edition” compare Segnan (2010). 
214 Zauber (2010) 
Australia, Canada phase 
in population-based 
screening 
Colonoscopy main 
screening-test in US 
only few well organized, 
nationwide, population-
based screening 
programs 
EU publishes first 
edition of guidelines for 
quality assurance in 
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sults of local pilot programs into account.215 The United States Preventive 
Services Task Force addresses the heterogeneous US-healthcare system 
where only the Veterans Administration runs a CRC-screening program. 
Compare table 4.9-1 for CRC-screening recommendations by the three in-
dependent HTA/ Review-Institutions the core of this report relies on. 
 
Table 4.9-1: CRC-screening recommendations from three independent institutions 
Institution 
 
Date Recommendation Comment 
Health Council of the 
Netherlands 
NL 
2009  55-75 years 
 iFOBT 75 ng/ml 
 every 2 years 
- 
United States Preventive 
Services Task Force 
USPSTF 
US 
2008  50-75 years 
 
 FOBT or 
 flexible sigmoidoscopy 
or 
 colonoscopy 
 first USPSTF recommendation for CRC-
screening in 1996 
 current recommendations based on update of 
2002 systematic review 
 previous USPSTF recommendations from 2002 
do not suggest upper limit of screening-age 
Ontario Health Technology 
Advisory Committee 
OHTAC 
CAN 
2009  from 50 years 
 FOBT 
 every 2 years 
- 
 
Abbreviations: CRC … colorectalcarcinoma 
 FOBT … faecal occult blood test 
 iFOBT … immunochemical faecal occult blood test 
 ng/ml … nanogram per millilitre  
Source: Health Council of the Netherlands (2009), USPSTF (2008), OHTAC (2009) 
 
The production of guidelines is generally not a straight-forward process: 
 “Although the term evidence-based may suggest that guidelines simply 
emerge from evidence, guidelines making is a human process, like creating 
and operating a judicial system is a human process, requiring structure and 
process to make it function properly. In other words, it is inherently a politi-
cal process and should be managed as such.”216 
Screening for CRC has a rapidly evolving science base, such that guidance 
may be expected to change as additional research becomes available.217 This 
may for instance be happening in regards to flexible sigmoidoscopy screen-
ing after the recent publications of three large randomised controlled tri-
als218: 
“Colorectal cancer screening guidelines usually recommend flexible sigmoi-
doscopy with a five year screening interval. In light of the UK trial, longer 
screening intervals should be recommended.”219 
                                                             
215 Health Council of the Netherlands (2009) 
216 Imperiale (2010) 
217 USPSTF Whitlock (2008a) 
218following quote refers to UK-trial: Atkin (2010) 
219 Betthauer (2010) p. 1260 
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4.10 Cost-effectiveness analysis of CRC-
screening 
For a review of cost-effectiveness analyses of alternative CRC-screening op-
tions and an introduction to important program-cost drivers in CRC-
screening compare part two of this report series.220 
4.11 Detailed CRC-screening program 
recommendations, the example of the 
Netherlands 
After evaluationg the merits and drawbacks of possible CRC-screening 
strategies – compare table 4.11-1 below – the Health Council of the Nether-
lands made the following recommendations for a population based CRC-
screening program in the Netherlands. 
 
Criteria 
 simplicity 
 acceptance 
 performance/ test characteristics 
 safety 
 
Recommendation for CRC-screening in NL 
 immunochemical Faecal Occult Blood Test (iFOBT), a self test 
 product: OC-sensor 
 single faecal sample 
 threshold 75 ng/ml (provisional recommendation due to lack of co-
lonoscopy capacity in NL today) 
 every 2 years 
 followed by colonoscopy in case of positive test result in outpatient 
clinic under sedation and with the aid of pain management 
 targeted group: women and men aged 55-75 
  (referral to screening after the age of 75 to be decided individually 
with GP) 
 
Anticipated results from modelling 
 number needed to treat for one CRC-death prevented 
 785 people would need to complete iFOBTs 
 40 follow-up colonoscopies 
                                                             
220 Patera N., Radlberger P., Schumacher I., Zechmeister I. Screening for Colorectal 
Cancer. Part 2: Health economic evaluations and aspects of screening-costs. HTA 
project report. 2012; 41b. available at http://eprints.hta.lbg.ac.at  
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effectiveness of CRC-
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 cost-effectiveness: EUR 2,200.- per life year gained (assuming partici-
pation rate of 60% derived from iFOBT-pilot trials conducted in the 
run up to the decision of introducing a national CRC-screening pro-
gram in NL) 
 
 
EUR 2,200.- per life year 
gained 
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Table 4.11-1: Health Council of the Netherlands: relative merit of six screening-methods 
 gFOBT 
 
iFOBT75 Molecular  
markers 
Colonoscopy Flexible  
Sigmoido-scopy 
CT –  
colonography 
Attendance 
 
+ ++ ? ? - ? 
Evidence 
 
++ + +/- +/- +/- +/- 
Test performance 
 
+/- ++ + ++ ++/- ++ 
Less burdensome 
 
+ ++ +   +/- 
Less risk 
 
++ ++ ++  + + 
Cost-effective 
 
+ ++ ? +? +? ? 
Less colonoscopy capacity needs 
 
++ + ?    
 
Abbreviations: CT … computed tomography 
 gFOBT … guaiac faecal occult blood test 
 iFOBT75 … immunochemical faecal occult blood test – threshold 75 nanograms per millilitre 
 
Source: 
 
adapted from table 5, Health Council of the Netherlands (2009) p. 80 
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5 Results part II: Questions to ask about CRC-
screening and program design 
5.1 Why is screening different from ordinary 
medical practice? 
Screening for disease is not a logical extension of ordinary medical practice. 
The ethical position is different. Screening involves an unsolicited offer to in 
principle healthy persons. These exceptional characteristics mean that 
screening is justified only if it is demonstrably advantageous. Proof of prin-
ciple alone – i.e. reduction of all-cause or disease-specific mortality through 
CRC-screening – is not enough for the introduction of screening: balancing 
of downsides with benefits is necessary.221 
Early detection must have a positive net health benefit. Only a minority of 
people undergoing screening stand to benefit directly from participation. In 
the case of CRC-screening, although CRC is a common cancer, the lifetime 
risk for an individual is actually quite low, 5%222 The lifetime mortality rate 
in the US is 2.4% for women and 3.3% for men.223 Of these, even if atten-
dance of CRC-screening was 100%, not all would benefit from it since some 
cancers would not be detected earlier and for other cancers early detection 
through screening does not prolongue life. So more than 95% of people have 
no benefit from CRC-screening but are still exposed to the potential harms 
of it. Even if CRC-screening was to completely eliminate CRC-cancer 
(which it does not), it is still necessary to carefully weigh up the pros and 
cons of any such program.224 As a cautious starting premise, it is by no 
means implausible that the desirable effects of a given form of screening will 
be outweighed by the undesirable effects: false positive results, false negative 
results, over-diagnosis, overtreatment etc.. As a consequence it is very impor-
tant that the design of a screening-program meets high quality standards, 
maximizes desirable effects and minimizes undesirable effects. Because a 
screening-program is made up of numerous diverse constituent activities, 
professional organization and effective management are vital.225 
Given potential harms and observed variability in test accuracy, emphasis on 
quality standards für implementation of any operator-dependent CRC-
screening test appears prudent.226 
                                                             
221 e.g. Health Council of the Netherlands (2009), Raffle (2009), Saul H. Interview 
with Michael Baum: Shooting sacred cows. Cancer Futures 2003;2;273-8 
222 e.g. Baxter (2010); US CRC-lifetime risk males 5.9% (lifetime mortality rate 
2.4%), females 5.4% (lifetime mortality rate 3.3%) - USPSTF Whitlock (2008a) 
223 USPSTF Whitlock (2008a) 
224 Health Council of the Netherlands (2009) p. 33 
225 Health Council of the Netherlands (2009) p. 107 
226 USPSTF Whitlock (2008) 
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5.2 What is NOT known about CRC-
screening? 
At this point in time reliable evidence is lacking in some areas giving rise to 
uncertainties and open questions about CRC-screening. These areas of un-
certainty still need to be dealt with when establishing an organized program: 
5.2.1 Natural course of CRC 
 one of the most uncertain assumptions is that all CRC arises from ad-
enomas227 
 frequency and malignant potential of hyperplastic and flat polyps in 
populations/ true underlying population prevalence of adenomas is 
uncertain228 
 
5.2.2 Effectiveness of CRC-screening 
 ??? no high-grade evidence (randomized controlled trials) for impact 
of any form of CRC-screening on all-cause mortality 
 ??? no high-grade evidence for reduction of disease-specific mortality 
other than for CRC-screening with gFOBT and flexible sigmoido-
scopy  
 none for colonoscopy (expected in 10+ years), CT-
colonography, capsule endoscopy, other biomarker tests 
 ??? evidence from screening-settings very limited229, including on 
complications230- there is evidence that complications might have 
been underestimated231; Norway’s NORCCAP is the only study on 
flexible sigmoidoscopy that is truly population based and will provide 
an estimate of screening impact after 10 years of follow up in 2013.232 
Spain’s COLONPREV is the only truly population based study on 
iFOBT and colonoscopy, results are expected in a decade.233 
 ??? even for gFOBT, which has been extensively investigated, a lack of 
certainty about true performance characteristics – particularly for 
newer versions of the test – remains. For iFOBT numerous test are 
available with heterogeneous performance characteristics.234 
                                                             
227 Wilschut (2011) 
228 Sharp (2012) 
229 e.g. Lieberman (2009), Brenner (2010) 
230 e.g. Lieberman (2009), Betthauer (2010) 
231 e.g. Leffler (2010) 
232 Hoff (2009) 
233 Quintero (2012) 
234 Sharp (2012) 
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5.2.3 Optimal setting of relevant CRC-screening 
parameters 
 ??? optimal referral threshold (number of polyps, size of polyps) 
 ? iFOBT to colonoscopy 
 ? flexible sigmoidoscopy to colonoscopy 
 appropriate polyp size threshold for referral to co-
lonoscopy is not well-established, thus colono-
scopy referral often follows detection of any lesion 
by flexible sigmoidoscopy235 
 ? CT- colonography to colonoscopy 
 ??? optimal screening-interval 
 ? iFOBT – 1 year?, 2 years?, more? 
 ? flexible sigmoidoscopy – possibly once only?236, 5 years?, 
10 years?237 
 ? colonoscopy238 – once only as a triage-test?239 10 years?, 
up to 20 years?, more? 
 recent evidence from epidemiological studies 
suggests that intervals for screening with colono-
scopy might be extended to 20 years or even long-
er, as subjects with negative findings at endoscopy 
are at very low risk for at least 20 more years240 
 the concept of using colonoscopy as a triage 
screening test offered at the age of 60 and used to 
classify persons as having low risk of CRC (no ad-
enomas detected) or high risk (adenomas de-
tected, particularly advanced ones), with no fur-
ther screening for the low risk group has been 
suggested241 
 ??? iFOBT 
 ? optimal test of the many available iFOBTs242 
 ? optimal number of stool samples to take243 
 ??? colonoscopy 
 there is some evidence of much lower yields of proximal/ 
right-sided vs. distal/ left-sided CRC, research is ongoing 
 ? causality of this difference not fully under-
stood244 
 ? repercussions for decision between colono-
                                                             
235 USPSTF Whitlock (2008a) 
236 Segnan (2011) 
237 Bretthauer (2010) 
238 e.g. Brenner (2010) 
239 Bretthauer (2012) 
240 e.g. Brenner (2008) 
241 Bretthauer (2012) 
242 e.g. Lieberman (2009) 
243 e.g. Hundt (2009), Lieberman (2009) 
244 e.g. Baxter (2009), Brenner (2010) 
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scopy and flexible sigmoidoscopy unad-
dressed245 
 ? hygiene standards and adverse events (e.g. double wash-
ing of endoscopic equipment and infectious disease trans-
mission) 
 ??? screening-program level 
 general 
 ? influence divergent rates of adenoma detection 
might have on screening-goal of prevention of 
CRC unclear246 
 does focus on detection rate (including 
detection of small adenomas) make 
sense? unknown share of adenomas that 
never become malignant are included as 
screening-benefit. 
 there is relatively small clinical benefit 
of detecting and removing very small 
polyps247 
 recommendation for screen-detected larger ade-
nomas >10mm is clear: removal; but optimal 
screening-regime for dealing with smaller ade-
nomas unclear 
 ? 6-10mm 
 ? < 6mm? 
 ? optimal surveillance regime 
 screening may induce lifestyle changes that might 
negatively affect benefit, e.g. 
o ? impact of negative polyp test 
on tobacco use248 
o ? impact of negative polyp test 
on dietary habits (obesity)249 
 test-specific program organization issues 
 ? iFOBT: management of interval between faecal 
sampling at individual’s home and analysis at lab 
 faecal samples used for iFOBT prone to 
denaturation: their quality is very impor-
tant 
 dating of samples by participants does 
not work well 
 storage/ temperature exposure of sample 
before arrival at analysis not easily con-
trollable 
o e.g. Australia (and potentially 
Canada) send out iFOBTs only 
in cooler months of the year250 
                                                             
245 e.g. Baxter (2010) 
246 e.g. Baxter (2010) 
247 e.g. Barclay (2006) 
248 e.g. Levin (2002) 
249 e.g. Levin (2002) 
250 Health Council of the Netherlands (2009) p. 114 
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 ? colonoscopy 
 formulation of program-aim aligned 
financial incentives for examiners 
difficult251 
o remuneration per screening-
colonoscopy? 
 caveat: incentive to per-
form screening-
colonoscopy rapidly 
o remuneration linked to yield 
(adenoma detected and re-
moved)? 
 caveat: if high adenoma 
detection rate really 
contributes to aim of 
screening-program (re-
duced all-cause mortal-
ity) is unknown 
o setting of colonoscopy remu-
neration relative to remunera-
tion for flexible sigmoidoscopy? 
 formulation of quality indicators for 
monitoring that are meaningful in 
terms of achieving program aim 
(documentation?, examiner experi-
ence?, withdrawal time of endoscope 
during which colon is examined?, 
completion rate?, hygiene stan-
dards?, yield? …)252 
 
 
                                                             
251 e.g. Barclay (2006), Gupta (2007), Lieberman (2009) 
252 e.g. Barclay (2006) 
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5.3 Essentials to keep in mind when 
designing a population based CRC-
screening program 
5.3.1 Program design 
Installation of screening-program structure with view to 
 assuring quality 
 sustainability 
 
Informed consent of screening-participants: inherent conflict of in-
terest: high participation rate crucial for program success 
 significance attached to ensuring that participation deci-
sions can be made freely increases253 
 non-participation must not entail negative conse-
quences for individuals, neither in relationship 
with their health insurance provider, nor with 
their physician254 
 ensuring that participation can be based on informed 
choice is vital for screening-program’s legitimacy 
o e.g.: FOBT testing 
 test itself entirely safe 
 positive test result implies referral for co-
lonoscopy 
 potential participants must therefore be 
made aware of the albeit small risk of se-
rious complications associated with co-
lonoscopy before they decide whether to 
have the initial “harmless” FOBT test255 
 informed choice is not easy to achieve 
o screening is a complex process not generally well 
understood by professionals and the public for a 
range of reasons256 
o decision-making about screening involves com-
plex risk assessment 
o many people overestimate the benefit of screening 
o screening-providers are inclined to stress benefits 
and trivialize drawbacks257 
 information to be given by program and provider inde-
pendent institution 
why? 
o (high) participation rate determines success of 
screening-program  program organizers biased 
o participation rate determines provider income  
operator/ examiner/ reader biased 
 
                                                             
253 Health Council of the Netherlands (2009) p. 99 
254 OHTAC (2009) p. 4 
255 Health Council of the Netherlands (2009) p. 101 
256 National Health Committee (2003) p. 2 
257 Health Council of the Netherlands (2009) p. 101 
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by who? 
o e.g. Nordic Cochrane Centre, Copenhagen, Den-
mark258 
o e.g. University of Hamburg, Fachwissenschaft Ge-
sundheit, Germany259 
 
“The decision to undergo screening should be a personal one. The 
aim of the medical community is simply to provide the individual 
with unbiased, informative and comprehensive information and 
comprehensive information about the advantages and disadvan-
tages of screening.”260 
5.3.2 Offering potential participants a choice of 
first-line screening-test 
 Is choice valued in itself? 
o YES: e.g. one attitude survey conducted among 
colonoscopy-naive individuals showed that, once 
they had been fully informed about the tech-
niques in question, most people preferred FOBT-
screening to colonoscopy261 
o possible options for choice in CRC-screening 
 FOBT or colonoscopy 
 FOBT or flexible sigmoidoscopy 
o consideration could be given to investigating the 
feasibility of combining flexible sigmoidoscopy-
screening with FOBT-screening and offering the 
choice between the two methods262 
 Is choice a tool to increase participation? 
o NO: currently no data available to support that 
implementing a multi-option program would re-
sult in higher participation or increase the effec-
tiveness of screening263 
 
                                                             
258 download for breast cancer screening in English: 
www.cochrane.dk/screening/index-en.htm or in German: 
http://www.cochrane.dk/screening/index-de.htm , accessed March 14th, 2010 
259 download for CRC-screening in German: http://www.gesundheit.uni-
hamburg.de/cgi-bin/newsite/index.php?page=page_46 , accessed March 14th, 2010 
260 Bretthauer (2011) p. 96 
261 Health Council of the Netherlands (2009) p. 62 
262 Health Council of the Netherlands (2009) p. 81 
263 Health Council of the Netherlands (2009) p. 93 
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5.3.3 Selection of screening-test(s) to use in 
population based program 
 expected influence of a test/ choice of tests on participa-
tion rate central for program’s decision 
“’The best test is the one that the patient will accept’ was 
often stated by experts”264 
 program test characteristics (incorporating participation 
rate) matter from a public health point of view – single 
test characteristics are of only theoretical interest 
 evidence of test characteristics in real-world setting/ 
screening-context relevant, not evidence from artificial 
trial setting/ symptomatic-test setting 
 the greater the sensitivity of a test (e.g. colonoscopy) for 
gradually developing abnormalities (e.g. CRC), the less 
advantage there is in having a shorter test interval265 
 
5.3.4 Program guidelines 
 development of integrated (multidisciplinary) guidelines 
covering the entire chain from screening to diagnosis, 
treatment, follow-up and surveillance as evidence-based 
backbone of population based screening-program 
 
 
5.3.5 Quality 
 if the potential benefit of screening is to be realized, steps 
must be taken to ensure that the quality of colonoscopy 
examinations is of an appropriate standard266  
o all screening-designs, independent of initial test 
(gFOBT, iFOBT, flexible sigmoidoscopy), ultimately 
rely on colonoscopy for effectiveness 
o if an adenoma is detected, the most important issue is 
that the abnormality will be fully removed during pol-
ypectomy 
 the biggest risk factor for adenoma patients in re-
lation to the development of CRC is incomplete 
adenoma removal267 
                                                             
264 Imperiale (2010) p. 1642 
265 Health Council of the Netherlands (2009) p. 95 
266 Health Council of the Netherlands (2009) p. 118 
267 Health Council of the Netherlands (2009) p. 119 
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 quality of endoscopists (training, continued education and 
experience) determines screening-yield and rate of adverse 
events 
o roles of different health professions in screening-
program (capabilities, legal requirements, …) – e.g. 
nurse endoscopists 
 provision of necessary quantity of qualified human re-
sources for screening 
 CRC beyond screening: professional staff and facilities for 
diagnosis and treatment need to be sufficiently well devel-
oped to cope with the volume of referrals that a national 
screening-program would generate 
 screening is only desirable once the necessary follow-
up care capacity has been built up 
 Process of Quality Assurance 
 accreditation for endoscopists 
o experience 
o continued education 
o meeting of process parameters, e.g. 
 proof of full colonoscopy (image of 
cecum) 
 withdrawal time 
 adenoma detection rate 
 complication rate 
 installation of reliable system to gather data on unin-
tended consequences of screening activity (i.e. hospi-
tal stays after screening endoscopies)268 
 quality assurance is more difficult but still essential in 
those areas, the screening-program does not have di-
rect management or funding control over 
o depending on local health care system: diag-
nostics, treatment, surveillance … 
 follow procedural and data protocol including stan-
dardized, uniform documentation of detected abnor-
malities (essential for evaluation) 
 pathology diagnoses will be the primary outcome on 
which the program is evaluated269 
 quality assurance in the domain of pathology 
is key 
 special considerations according to chosen screening-
test: e.g. in the case of iFOBT-based screening 
o iFOB-testing is automated and its quality is 
easy to control 
o focus of quality assurance therefore not on 
the screening-test itself but on 
 organization of sample transport 
from participants to lab 
 follow-up testing and examination 
(colonoscopy, histopathology) 
 
                                                             
268 e.g. Leffler (2010) 
269 Health Council of the Netherlands (2009) p. 126 
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5.3.6 Surveillance 
 design of surveillance270 thresholds has mayor impact on 
number of colonoscopies resulting from screening  un-
managed program may easily lead to explosion in number 
of surveillance colonoscopies 
 existing CRC-surveillance regimes practiced the world 
over today are problematic 
o population-based screening-program calls for re-
formulation: underlying guidelines were intended 
for normal clinical practice rather than for 
screen-detected adenomas 
o current guidelines are stricter than supported by 
scientific evidence 
o (already strict) guidelines interpreted even stricter 
in actual practice  too many patients are under-
going surveillance colonoscopies 
 elements of colonoscopy capacity271 
1. screening 
2. diagnosis, polypectomy (polyp removal) 
3. surveillance (25-40 % today, present level increas-
ingly seen as excessive, danger of further increase 
through unmanaged screening-program) 
o of the above, surveillance colonoscopy has 
 lowest yield 
 worst benefit-harms trade-off 
 benefit of screening of people with family history of CRC 
under 55 unclear 272 
4. screening 
5. diagnosis, polypectomy (polyp removal) 
6. surveillance (25-40 % today, present level increas-
ingly seen as excessive, danger of further increase 
through unmanaged screening-program) 
o of the above, surveillance colonoscopy has 
 lowest yield 
 worst benefit-harms trade-off 
 
                                                             
270 Health Council of the Netherlands (2009) p. 120; for examples on surveillance 
guidelines by EPAGE II compare Arditi (2009); for American Cancer Society and 
US Multi-Society Task Force on Colorectal Cancer recommendations compare 
Brooks (2008) 
271 Health Council of the Netherlands (2009) p. 120 
272 IQWiG (2012) 
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5.3.7 Flexibility 
 culture of flexibility independent of initial program setup 
desirable 
 mission statement: “Our screening-program focuses on the 
maximum benefit for the population.” 
o ongoing critical evaluation by program itself and 
through independent (outside/ foreign) institu-
tion 
o openness to new (scientific or evidence) develop-
ments 
 mission statement not: “Our screening-
program conducts the best possible 
screening with the chosen test X.” as this 
would result in locking-in of initial deci-
sions 
 a new test could be introduced within the existing infra-
structure of the operational program, since various key el-
ements of a CRC-program – such as a call/recall system, a 
system for documentation and quality assurance as well as 
colonoscopy capacity – would be test-independent273 
5.3.8 International and research focus 
 program culture focusing on international best-practice 
o transparency 
o sharing knowledge 
o investing in partnership 
o learning from each other 
o (research) leadership 
 enable program to generate new scientific evidence 
o before introduction of program: setting up of smaller 
pilot projects generating specific national data needed 
for conceptualization of nationwide screening-
program 
 e.g. NL274 
o during roll-out: due to small effect sizes involved in 
screening-studies: randomized trials on screening-
effectiveness need large number of participants and 
long follow-up to establish effectiveness of preventing 
deaths, especially set up trials are expensive  in ab-
sence of trials the results of screening may remain in-
conclusive 
 roll-out of screening-program offers possibil-
ity for experimental design to gather evi-
dence on effectiveness of screening at small 
additional cost 
 every population based public health pro-
gram for CRC-screening using any primary 
test modality should be launched with ran-
                                                             
273 Health Council of the Netherlands (2009) p. 81 
274 Health Council of the Netherlands (2009) 
critical program 
evaluation also from 
independent outside 
institution 
 
program should be open 
to incorporating rapidly 
evolving science-base of 
CRC-screening 
program to both learn 
from and inform 
international best 
practice 
 
(small) pilot projects in 
context of screening-
program to generate 
new scientific 
evidence… 
 
… before, 
… during, 
… after  
 
… roll-out of screening-
program 
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domization of the target population at the 
implementation phase275 
o after introduction of program: program evaluation 
and introduction of pilots within the larger screening-
program 
 e.g. design of program should enable trials of 
potentially preferable test methods per-
formed as flanking studies within the context 
of the operational program276 
 public funding of research necessary 
“The UK trial [on flexible sigmoidoscopy in CRC-
Screening]277 illustrates the value of long term publicly funded 
medical research. The study was designed in the early 1990s, 
and the main results are available almost 20 years later. Many 
people argue that medicine is developing so rapidly that a trial 
of this duration would be outdated by the time the results are 
available. This landmark study shows that this is a false as-
sumption. It is important that large funding organizations like 
the UK National Health System, the European Union, and oth-
ers support long term clinical trials that tackle important health 
problems beyond the often short term scope of industry funded 
medical research.”278 
5.3.9 Consideration of phased/staged introduction 
 roll-out of CRC-screening program is complex 
 ‘teething problems’ during initial stage of newly estab-
lished program more easily addressed with phased intro-
duction 
 first stages of introduction can provide necessary data for 
calibrating national program 
 roll-out options Switzerland 
o local 
o regional 
o national 
5.3.10 Program financing 
 well managed screening needs resources for program over-
head 
o call/recall system 
o training, continued education and program-
accreditation of examiners 
o data/ IT system 
o quality assurance 
o from the outset, budgetary provision should also be 
made for 
                                                             
275 e.g. Malila (2008) 
276 Health Council of the Netherlands (2009) p. 82 
277 Atkin (2010) 
278 Betthauer (2010) p. 1260 
staged introduction of 
screening-program 
offers advantages 
sustainable and 
comprehensive 
financing of program 
necessary to achieve 
screening-goals 
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 monetary provisions for independent infor-
mation of participants 
 program-internal monitoring of ongoing 
screening-activites 
 regular program evaluation from independ-
ent (outside/foreign) institution 
 reference system 
 promotion of knowledge and innovation-
oriented scientific research, necessary to keep 
the screening-program up to date 
 
screening overhead 
expensive … 
… achieving high 
participation rate 
possibly, too 
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6 Conclusion 
 program design (quality) and participation rate matter 
 choice of screening-test is of secondary importance279 
 
 
 
 CRC-screening is not simply about choosing the right initial 
test for screening 
 
 effective CRC-screening is about establishing a quality assured 
screening-program integrating diagnosis, treatment and sur-
veillance 
o emphasis on quality focused human resource devel-
opment of endoscopists 
 
 uptake is the primary determinant of effectiveness for a screen-
ing-program 
 
 level of regular participation and the resulting effective pro-
gram-sensitivity has a greater influence than the sensitivity of a 
single performance of a screening-test280 particularly in the 
context of a population-based screening-program for slowly de-
veloping abnormalities (e.g. for CRC)281 
 study of determinants of participation rate warranted 
to inform program design282 
 
 quality of screening-program (narrower realm of screening plus 
integration of diagnosis – treatment – surveillance) affects de-
sired outcome of mortality reduction and minimization of neg-
ative repercussions on screened population 
 
 
                                                             
279 „In the end, a test can only provide benefit if it is actually done.”, Church (2011) 
“Patient preferences for screening tests should be identified and respected – in this 
case the best test is the one that gets done.”, Inadomi (2012) 
“The role of adherence is key to understanding which CRC tests provide higher life 
years gained at reasonable resource use and cost.”, Zauber (2010) 
280 Health Council of the Netherlands (2009) p. 99 
281 Health Council of the Netherlands (2009) p. 95 
282 e.g. Holden (2010) 
 
integration of screening, 
diagnosis, treatment 
and surveillance fosters 
quality 
focus should be put on 
training and continued 
education of 
endoscopists 
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8 Appendices 
8.1 Appendix A: Systematic health technology reviews on CRC-screening issues from major HTA-
institutions 
 Institution Titel 
 
Remark 
 
1. Health Council of 
the Netherlands 
Health Council of the Netherlands. A national colorectal cancer screening programme. The 
Hague: Health Council of the Netherlands, 2009; publication no. 2009/13E 
Comprehensive analysis of questions around the establish-
ment of a population based CRC-screening program in the 
Netherlands, contains systematic review of the literature 
2. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation state-
ment. U.S. Preventive Services Task Force. Ann Intern Med. 2008 Nov 4;149(9):627-37. Epub 
2008 Oct 6. 
United States Preventive Services Task Force recommendation 
3. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, up-
dated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 
Nov 4;149(9):638-58. Epub 2008 Oct 6. Review. 
United States Preventive Services Task Force: systematic re-
view published in journal 
4. 
US 
Preventive 
Services 
Task  
Force 
Whitlock, EP, Lin J, Liles E, Beil T, Fu R, O’Connor E, Thompson RN, Cardenas T. Screening for 
Colorectal Cancer: An Updated Systematic Review. Evidence Synthesis No. 65, Part 1. AHRQ 
Publication No. 08-05124-EF-1. Rockville, Maryland, Agency for Healthcare Research and 
Quality, October 2008 
United States Preventive Services Task Force: full systematic 
review 
5. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Pre-
ventive Services Task Force. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van 
Ballegooijen M, Kuntz KM. Ann Intern Med. 2008 Nov 4;149(9):659-69. Epub 2008 Oct 6. 
United States Preventive Services Task Force: modelling for 
economic evaluation of alternative CRC-screening strategies 
published in journal 
6. 
US 
Preventive 
Services 
Task  
Force 
Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. 
Evaluating Test Strategies for Colorectal Cancer Screening—Age to Begin, Age to Stop, and 
Timing of Screening Intervals: A Decision Analysis of Colorectal Cancer Screening for the U.S. 
Preventive Services Task Force from the Cancer Intervention and Surveillance Modeling 
Network (CISNET). Evidence Synthesis No. 65, Part 2. AHRQ Publication No. 08-05124-EF-2.
Rockville, Maryland, Agency for Healthcare Research and Quality, March 2009. 
United States Preventive Services Task Force: full economic 
evaluation 
7. Medical Advisory Secretariat. Screening methods for early detection of colorectal cancers 
and polyps. Ontario Health Technology Assessment Series 2009;9(6-11). 
Ontario Health Technology Assessment 
Summary and compilation of six reports below 
8. 
Ontario 
HTA 
Medical Advisory Secretariat. Screening methods for early detection of colorectal cancers 
and polyps: summary of evidence-based analyses. Ontario Health Technology Assessment 
Series 2009;9(6). 
Ontario Health Technology Assessment 
Screening for Colorectal Cancer 
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9. Medical Advisory Secretariat. Computed tomographic (CT) colonography for colorectal can-
cer screening: an evidence-based analysis. Ontario Health Technology Assessment Series 
2009;9(7). 
Ontario Health Technology Assessment  
Review - CT-Colonography 
10. Medical Advisory Secretariat. Magnetic resonance (MR) colonography for colorectal cancer 
screening: an evidence-based analysis. Ontario Health Technology Assessment Series 
2009;9(8). 
Ontario Health Technology Assessment 
Review – MR-Colonography 
11. Medical Advisory Secretariat. Capsule Endoscopy for Colorectal Cancer Screening: an evi-
dence-based analysis. Ontario Health Technology Assessment Series 2009;9(9). 
Ontario Health Technology Assessment 
Review - Capsule Endoscopy 
12. Medical Advisory Secretariat. Fecal Occult Blood Test for Colorectal Cancer Screening: an ev-
idence-based analysis. Ontario Health Technology Assessment Series 2009;9(10). 
Ontario Health Technology Assessment 
Review - Fecal Occult Blood Test 
13 
Ontario 
HTA 
Medical Advisory Secretariat. Flexible sigmoidoscopy for colorectal cancer screening: an evi-
dence-based analysis. Ontario Health Technology Assessment Series 2009;9 (11). 
Ontario Health Technology Assessment 
Review – Flexible Sigmoidoscopy 
14. Mujoomdar M, Cimon K, Spry C. Fecal Immunochemical Tests for Colorectal Cancer Screen-
ing: A Systematic Review of Accuracy and Compliance. Ottawa: Canadian Agency for Drugs 
and Technologies in Health; 2009 
Canadian Agency for Drugs and Technologies in Health 
(CADTH) 
Review – Immunochemical Tests plus compliance 
15. Ho C, Heitman S, Membe SK, Morrison A, Moulton K, Manns B, Au F, Reed M, Hilsden R. 
Computed tomographic colonography for colorectal cancer screening in an average risk pop-
ulation: Systematic review and economic evaluation. [Technology report number 114]. Ot-
tawa: Canadian Agency for Drugs and Technologies in Health; 2008 
Canadian Agency for Drugs and Technologies in Health 
(CADTH) 
 
Review – CT-Colonography 
16. Tran K. Capsule colonoscopy: PillCam® Colon [Issues in emerging health technologies issue 
106].Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007 
Canadian Agency for Drugs and Technologies in Health 
(CADTH) 
Capsule Endoscopy 
17. 
Canada 
HTA 
Ho C, Jacobs P, Sandha G, Noorani HZ, Skidmore B. Non-physicians performing screening 
flexible sigmoidoscopy: clinical efficacy and cost-effectivenes [Technology report no 60]. Ot-
tawa: Canadian Coordinating Office for Health Technology Assessment; 2006 
Canadian Agency for Drugs and Technologies in Health 
(CADTH) 
Non physician flexible sigmoidoscopy examiners 
18. Denmark 
HTA 
Christensen, LA; Dahlerup, JF; Poulsen, PB; Thranholm L Capsule endoscopies of the small in-
testine – a Health Technology Assessment Copenhagen: National Board of Health, Danish 
Centre for Health Technology Assessment, 2007 Danish Health Technology Assessment –
Projects funded by Dacehta 2007; 7 (1) 
Danish Centre for Health Technology Assessment  
Capsule Endoscopy 
English summary of report in Danish 
19. Danish 
HTA 
National Board of Health, Monitoring & Health Technology Assessment Screening for colo-
rectal cancer: The significance of participation rates – A Health Technology Assessment Co-
penhagen: Danish National Board of Health, Monitoring & Health Technology Assessment, 
2008 Health Technology Assessment 2008; 10(1) 
Danish Centre for Health Technology Assessment 
On the importance of participation rates 
English summary of report in Danish 
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20. UK 
NHS 
 
Tappenden P, Eggington S, Nixon R, Chilcott J, Sakai H, Karnon J. Colorectal cancer screening 
options appraisal. Cost-effectiveness, cost-utility and resource impact of alternative screen-
ing options for colorectal cancer. Report to the English Bowel Cancer Screening Working 
Group. University of Sheffield, 2004 
Bericht fu¨r NHS Bowel Cancer Screening Programme 
 
Colorectal cancer screening options appraisal 
21. Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer. Arditi 
C, Peytremann-Bridevaux I, Burnand B, Eckardt VF, Bytzer P, Agre´us L, Dubois RW, Vader JP, 
Froehlich F, Pittet V, Schussele´ Filliettaz S, Juillerat P, Gonvers JJ; EPAGE II Study Group. En-
doscopy. 2009 Mar;41(3):200-8. Epub 2009 Mar 11. Review. 
European Panel on the Appropriateness of Gastrointestinal 
Endoscopy (EPAGE II) 
Review von Guidelines, Systematic Reviews und Prima¨rlitera-
tur 
22. 
Europe 
EPAGE II 
Appropriateness of colonoscopy in Europe (EPAGE II). Surveillance after polypectomy and 
after resection of colorectal cancer. Arditi C, Gonvers JJ, Burnand B, Minoli G, Oertli D, La-
caine F, Dubois RW, Vader JP, Schussele´ Filliettaz S, Peytremann-Bridevaux I, Pittet V, Juille-
rat P, Froehlich F; EPAGE II Study Group. Endoscopy. 2009 Mar;41(3):209-17. Epub 2009 
Mar 11. Review. 
European Panel on the Appropriateness of Gastrointestinal 
Endoscopy (EPAGE II) 
 
Guidelines fu¨r Surveillance 
23. US 
Multi 
Society 
Task 
Force 
Colonoscopy surveillance after polypectomy and colorectal cancer resection. Brooks DD, 
Winawer SJ, Rex DK, Zauber AG, Kahi CJ, Smith RA, Levin B, Wender R; U.S. Multi-Society 
Task Force on Coloretal Cancer; American Cancer Society. Am Fam Physician. 2008 Apr 
1;77(7):995-1002. 
U.S. Multi-Society Task Force on Colorectal Cancer and the 
American Cancer Society 
 
Consensus Guidelines 
24. US 
Institute for Clini-
cal and Economic
Review 
Scherer R, Knudsen A, Pearson SD CT Colonography for colorectal cancer screening – Final 
appraisal document. Institute for Clinical and Economic Review ICER, 2008 
Institute for Clinical and Economic Review ICER (private) 
 
Colonography 
 
Screening for Colorectal Cancer 
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8.2 Appendix B: 13 primary literature references from hand search 2009 not cited in report 
Article 
 
Topic / question addressed 
(in German) 
BAXTER 2010 Editorial zu Effectiveness von Koloskopie 
Anlass: Studie u¨ber unterschiedliche Entdeckungsraten im linken (distalen) und rechten (proximalen) Kolon (BRENNER JNCI 
2010) 
EKELUND 2006 Kritische Fragen zu Evidenz fu¨r Screening 
ELIAKIM 2006 Kapselendoskopie 
ELIAKIM 2009 Kapselendoskopie 
HAKAMA 2005 Artikel, auf den EKELUND Acta Oncologica 2006 kritisch antwortet 
HAKAMA response to EKELUND 2006 Antwort auf EKELUND Acta Oncologica 2006 
MALILA 2007 Follow-up nach 25 Jahren von finnischer Population, an FOBT Screening teilnahm 
PINEDA 2008 Darmvorbereitung vor operativem Eingriff – Meta-Analyse und Systematic Review 
RAMOS 2008 Review zum Einfluss von Zeitpunkt von Diagnose und Therapie auf Staging von kolorektal Krebs 
SCHOOFS 2006 Kapselendoskopie 
SIEG 2009 Kapselendoskopie 
VAN DEN BROEK 2009 Review eines alternativen Koloskopieverfahrens: narrow band imaging 
VAN GILS 2009 Review zu Annahmen u¨ber Teilnahmeraten in der o¨konomischen Evaluation von Screening 
 
 
